false2024Q3000073176612/3150xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesutr:Ratexbrli:pureunh:reportableSegments00007317662024-01-012024-09-3000007317662024-10-3100007317662024-09-3000007317662023-12-3100007317662024-07-012024-09-3000007317662023-07-012023-09-3000007317662023-01-012023-09-300000731766us-gaap:ProductMember2024-07-012024-09-300000731766us-gaap:ProductMember2023-07-012023-09-300000731766us-gaap:ProductMember2024-01-012024-09-300000731766us-gaap:ProductMember2023-01-012023-09-300000731766us-gaap:ServiceMember2024-07-012024-09-300000731766us-gaap:ServiceMember2023-07-012023-09-300000731766us-gaap:ServiceMember2024-01-012024-09-300000731766us-gaap:ServiceMember2023-01-012023-09-300000731766us-gaap:CommonStockMember2024-06-300000731766us-gaap:AdditionalPaidInCapitalMember2024-06-300000731766us-gaap:RetainedEarningsMember2024-06-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-06-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000731766us-gaap:NoncontrollingInterestMember2024-06-3000007317662024-06-300000731766us-gaap:RetainedEarningsMember2024-07-012024-09-300000731766us-gaap:NoncontrollingInterestMember2024-07-012024-09-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-07-012024-09-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2024-07-012024-09-300000731766us-gaap:CommonStockMember2024-07-012024-09-300000731766us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000731766us-gaap:CommonStockMember2024-09-300000731766us-gaap:AdditionalPaidInCapitalMember2024-09-300000731766us-gaap:RetainedEarningsMember2024-09-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-09-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000731766us-gaap:NoncontrollingInterestMember2024-09-300000731766us-gaap:CommonStockMember2023-06-300000731766us-gaap:AdditionalPaidInCapitalMember2023-06-300000731766us-gaap:RetainedEarningsMember2023-06-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-06-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000731766us-gaap:NoncontrollingInterestMember2023-06-3000007317662023-06-300000731766us-gaap:RetainedEarningsMember2023-07-012023-09-300000731766us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-07-012023-09-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012023-09-300000731766us-gaap:CommonStockMember2023-07-012023-09-300000731766us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000731766us-gaap:CommonStockMember2023-09-300000731766us-gaap:AdditionalPaidInCapitalMember2023-09-300000731766us-gaap:RetainedEarningsMember2023-09-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-09-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000731766us-gaap:NoncontrollingInterestMember2023-09-3000007317662023-09-300000731766us-gaap:CommonStockMember2023-12-310000731766us-gaap:AdditionalPaidInCapitalMember2023-12-310000731766us-gaap:RetainedEarningsMember2023-12-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000731766us-gaap:NoncontrollingInterestMember2023-12-310000731766us-gaap:RetainedEarningsMember2024-01-012024-09-300000731766us-gaap:NoncontrollingInterestMember2024-01-012024-09-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-09-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300000731766us-gaap:CommonStockMember2024-01-012024-09-300000731766us-gaap:AdditionalPaidInCapitalMember2024-01-012024-09-300000731766us-gaap:CommonStockMember2022-12-310000731766us-gaap:AdditionalPaidInCapitalMember2022-12-310000731766us-gaap:RetainedEarningsMember2022-12-310000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000731766us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000731766us-gaap:NoncontrollingInterestMember2022-12-3100007317662022-12-310000731766us-gaap:RetainedEarningsMember2023-01-012023-09-300000731766us-gaap:NoncontrollingInterestMember2023-01-012023-09-300000731766us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-09-300000731766us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-09-300000731766us-gaap:CommonStockMember2023-01-012023-09-300000731766us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300000731766unh:ProductsAndServicesMember2024-09-300000731766unh:ProductsAndServicesMember2023-12-3100007317662024-10-012024-09-300000731766us-gaap:USTreasuryAndGovernmentMember2024-09-300000731766us-gaap:USStatesAndPoliticalSubdivisionsMember2024-09-300000731766us-gaap:CorporateDebtSecuritiesMember2024-09-300000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2024-09-300000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2024-09-300000731766us-gaap:USTreasuryAndGovernmentMember2023-12-310000731766us-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-310000731766us-gaap:CorporateDebtSecuritiesMember2023-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2023-12-310000731766us-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2023-12-310000731766us-gaap:DebtSecuritiesMember2024-09-300000731766us-gaap:DebtSecuritiesMember2023-12-310000731766us-gaap:FairValueInputsLevel1Member2024-09-300000731766us-gaap:FairValueInputsLevel2Member2024-09-300000731766us-gaap:FairValueInputsLevel3Member2024-09-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMember2024-09-300000731766us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMember2024-09-300000731766us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMember2024-09-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2024-09-300000731766us-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2024-09-300000731766us-gaap:FairValueInputsLevel3Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2024-09-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2024-09-300000731766us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2024-09-300000731766us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2024-09-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2024-09-300000731766us-gaap:FairValueInputsLevel2Memberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2024-09-300000731766us-gaap:FairValueInputsLevel3Memberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2024-09-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2024-09-300000731766us-gaap:FairValueInputsLevel2Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2024-09-300000731766us-gaap:FairValueInputsLevel3Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2024-09-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:DebtSecuritiesMember2024-09-300000731766us-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMember2024-09-300000731766us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2024-09-300000731766us-gaap:FairValueInputsLevel1Member2023-12-310000731766us-gaap:FairValueInputsLevel2Member2023-12-310000731766us-gaap:FairValueInputsLevel3Member2023-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:USTreasuryAndGovernmentMember2023-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:USTreasuryAndGovernmentMember2023-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMember2023-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:USStatesAndPoliticalSubdivisionsMember2023-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2023-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2023-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:MortgageBackedSecuritiesIssuedByUSGovernmentSponsoredEnterprisesMember2023-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2023-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2023-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:MortgageBackedSecuritiesIssuedByPrivateEnterprisesMember2023-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:DebtSecuritiesMember2023-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:DebtSecuritiesMember2023-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:DebtSecuritiesMember2023-12-310000731766us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2024-09-300000731766us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMember2024-09-300000731766us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2024-09-300000731766us-gaap:FairValueMeasurementsNonrecurringMember2024-09-300000731766us-gaap:LongTermDebtMember2024-09-300000731766us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-12-310000731766us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-12-310000731766us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsNonrecurringMember2023-12-310000731766us-gaap:FairValueMeasurementsNonrecurringMember2023-12-310000731766us-gaap:LongTermDebtMember2023-12-3100007317662024-03-310000731766unh:A4.600NotesDueApril2027Member2024-03-310000731766unh:A4.700NotesDueApril2029Member2024-03-310000731766unh:A4.900NotesDueApril2031Member2024-03-310000731766unh:A5.000NotesDueApril2034Member2024-03-310000731766unh:A5.375NotesDueApril2054Member2024-03-310000731766unh:A5.500NotesDueApril2064Member2024-03-3100007317662024-07-310000731766unh:FloatingRateNotesDueJuly2026Member2024-07-310000731766unh:A4.750NotesDueJuly2026Member2024-07-310000731766unh:A4.800NotesDueJanuary2030Member2024-07-310000731766unh:A4.950NotesDueJanuary2032Member2024-07-310000731766unh:A5.150NotesDueJuly2034Member2024-07-310000731766unh:A5.500NotesDueJuly2044Member2024-07-310000731766unh:A5.625NotesDueJuly2054Member2024-07-310000731766unh:A5.750NotesDueJuly2064Member2024-07-310000731766us-gaap:CommercialPaperMember2024-09-300000731766unh:May2024364DayRevolvingBankCreditFacilityMember2024-05-310000731766unh:May2024364DayRevolvingBankCreditFacilityMember2024-05-012024-05-310000731766unh:May2024364DayDelayedDrawTermLoanMember2024-05-310000731766unh:May2024364DayDelayedDrawTermLoanMember2024-05-012024-05-310000731766us-gaap:CustomerRelatedIntangibleAssetsMember2024-01-012024-09-300000731766unh:TrademarksAndTechnologyMemberMember2024-01-012024-09-300000731766us-gaap:OtherIntangibleAssetsMember2024-01-012024-09-3000007317662024-03-192024-03-1900007317662024-06-252024-06-2500007317662024-09-242024-09-240000731766us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2024-01-012024-09-300000731766us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-01-012024-09-300000731766us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember2024-09-300000731766unh:OtherDispositionsMember2024-01-012024-09-3000007317662024-02-062024-02-060000731766us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember2024-02-060000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumHealthMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumInsightMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumRxMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberunh:TotalOptumMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMember2024-07-012024-09-300000731766unh:ExternalCustomersMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:UnitedhealthcareMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumHealthMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumInsightMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumRxMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMemberus-gaap:ProductMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:ProductMemberunh:TotalOptumMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMemberus-gaap:ProductMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:ProductMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:UnitedhealthcareMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumHealthMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumInsightMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumRxMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMemberus-gaap:ServiceMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:ServiceMemberunh:TotalOptumMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:ServiceMember2024-07-012024-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2024-07-012024-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumHealthMember2024-07-012024-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumInsightMember2024-07-012024-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumRxMember2024-07-012024-09-300000731766unh:IntersegmentMemberus-gaap:IntersegmentEliminationMember2024-07-012024-09-300000731766unh:IntersegmentMemberunh:TotalOptumMember2024-07-012024-09-300000731766unh:IntersegmentMemberus-gaap:CorporateNonSegmentMember2024-07-012024-09-300000731766unh:IntersegmentMember2024-07-012024-09-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2024-07-012024-09-300000731766us-gaap:OperatingSegmentsMemberunh:OptumHealthMember2024-07-012024-09-300000731766us-gaap:OperatingSegmentsMemberunh:OptumInsightMember2024-07-012024-09-300000731766us-gaap:OperatingSegmentsMemberunh:OptumRxMember2024-07-012024-09-300000731766us-gaap:IntersegmentEliminationMember2024-07-012024-09-300000731766unh:TotalOptumMember2024-07-012024-09-300000731766us-gaap:CorporateNonSegmentMember2024-07-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumHealthMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumInsightMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumRxMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberunh:TotalOptumMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMember2023-07-012023-09-300000731766unh:ExternalCustomersMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:UnitedhealthcareMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumHealthMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumInsightMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumRxMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMemberus-gaap:ProductMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:ProductMemberunh:TotalOptumMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMemberus-gaap:ProductMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:ProductMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:UnitedhealthcareMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumHealthMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumInsightMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumRxMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMemberus-gaap:ServiceMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:ServiceMemberunh:TotalOptumMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:ServiceMember2023-07-012023-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2023-07-012023-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumHealthMember2023-07-012023-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumInsightMember2023-07-012023-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumRxMember2023-07-012023-09-300000731766unh:IntersegmentMemberus-gaap:IntersegmentEliminationMember2023-07-012023-09-300000731766unh:IntersegmentMemberunh:TotalOptumMember2023-07-012023-09-300000731766unh:IntersegmentMemberus-gaap:CorporateNonSegmentMember2023-07-012023-09-300000731766unh:IntersegmentMember2023-07-012023-09-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2023-07-012023-09-300000731766us-gaap:OperatingSegmentsMemberunh:OptumHealthMember2023-07-012023-09-300000731766us-gaap:OperatingSegmentsMemberunh:OptumInsightMember2023-07-012023-09-300000731766us-gaap:OperatingSegmentsMemberunh:OptumRxMember2023-07-012023-09-300000731766us-gaap:IntersegmentEliminationMember2023-07-012023-09-300000731766unh:TotalOptumMember2023-07-012023-09-300000731766us-gaap:CorporateNonSegmentMember2023-07-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumHealthMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumInsightMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumRxMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberunh:TotalOptumMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMember2024-01-012024-09-300000731766unh:ExternalCustomersMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:UnitedhealthcareMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumHealthMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumInsightMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumRxMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMemberus-gaap:ProductMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:ProductMemberunh:TotalOptumMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMemberus-gaap:ProductMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:ProductMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:UnitedhealthcareMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumHealthMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumInsightMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumRxMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMemberus-gaap:ServiceMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:ServiceMemberunh:TotalOptumMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:ServiceMember2024-01-012024-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2024-01-012024-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumHealthMember2024-01-012024-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumInsightMember2024-01-012024-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumRxMember2024-01-012024-09-300000731766unh:IntersegmentMemberus-gaap:IntersegmentEliminationMember2024-01-012024-09-300000731766unh:IntersegmentMemberunh:TotalOptumMember2024-01-012024-09-300000731766unh:IntersegmentMemberus-gaap:CorporateNonSegmentMember2024-01-012024-09-300000731766unh:IntersegmentMember2024-01-012024-09-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2024-01-012024-09-300000731766us-gaap:OperatingSegmentsMemberunh:OptumHealthMember2024-01-012024-09-300000731766us-gaap:OperatingSegmentsMemberunh:OptumInsightMember2024-01-012024-09-300000731766us-gaap:OperatingSegmentsMemberunh:OptumRxMember2024-01-012024-09-300000731766us-gaap:IntersegmentEliminationMember2024-01-012024-09-300000731766unh:TotalOptumMember2024-01-012024-09-300000731766us-gaap:CorporateNonSegmentMember2024-01-012024-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumHealthMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumInsightMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberunh:OptumRxMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberunh:TotalOptumMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMember2023-01-012023-09-300000731766unh:ExternalCustomersMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:UnitedhealthcareMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumHealthMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumInsightMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ProductMemberunh:OptumRxMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMemberus-gaap:ProductMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:ProductMemberunh:TotalOptumMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMemberus-gaap:ProductMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:ProductMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:UnitedhealthcareMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumHealthMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumInsightMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:OperatingSegmentsMemberus-gaap:ServiceMemberunh:OptumRxMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:IntersegmentEliminationMemberus-gaap:ServiceMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:ServiceMemberunh:TotalOptumMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:CorporateNonSegmentMemberus-gaap:ServiceMember2023-01-012023-09-300000731766unh:ExternalCustomersMemberus-gaap:ServiceMember2023-01-012023-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2023-01-012023-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumHealthMember2023-01-012023-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumInsightMember2023-01-012023-09-300000731766unh:IntersegmentMemberus-gaap:OperatingSegmentsMemberunh:OptumRxMember2023-01-012023-09-300000731766unh:IntersegmentMemberus-gaap:IntersegmentEliminationMember2023-01-012023-09-300000731766unh:IntersegmentMemberunh:TotalOptumMember2023-01-012023-09-300000731766unh:IntersegmentMemberus-gaap:CorporateNonSegmentMember2023-01-012023-09-300000731766unh:IntersegmentMember2023-01-012023-09-300000731766us-gaap:OperatingSegmentsMemberunh:UnitedhealthcareMember2023-01-012023-09-300000731766us-gaap:OperatingSegmentsMemberunh:OptumHealthMember2023-01-012023-09-300000731766us-gaap:OperatingSegmentsMemberunh:OptumInsightMember2023-01-012023-09-300000731766us-gaap:OperatingSegmentsMemberunh:OptumRxMember2023-01-012023-09-300000731766us-gaap:IntersegmentEliminationMember2023-01-012023-09-300000731766unh:TotalOptumMember2023-01-012023-09-300000731766us-gaap:CorporateNonSegmentMember2023-01-012023-09-30

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
__________________________________________________________ 
FORM 10-Q
__________________________________________________________ 
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2024
or
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
Commission File Number: 1-10864
__________________________________________________________ 
UHG(R)_CMYK.jpg
UnitedHealth Group Incorporated
(Exact name of registrant as specified in its charter)
 __________________________________________________________ 
Delaware41-1321939
(State or other jurisdiction of
incorporation or organization)		(I.R.S. Employer
Identification No.)
9900 Bren Road East55343655 New York Avenue NW20001
Minnetonka,
Minnesota
Washington,DC
(Address of principal executive offices) (Zip Code)(Address of principal executive offices)(Zip Code)
(800) 328-5979
(Registrant’s telephone number, including area code)
_________________________________________________________  
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $.01 par valueUNHNew York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act
Large accelerated filer☒Accelerated filer
☐
Non-accelerated filer
☐
Smaller reporting company
☐
Emerging growth company
☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes ☐ No ☒
As of October 31, 2024, there were 920,284,334 shares of the registrant’s Common Stock, $.01 par value per share, issued and outstanding.


UNITEDHEALTH GROUP
Table of Contents
 
  Page



PART I
ITEM 1.    FINANCIAL STATEMENTS
UnitedHealth Group
Condensed Consolidated Balance Sheets
(Unaudited)
(in millions, except per share data)September 30,
2024		December 31,
2023
Assets
Current assets:
Cash and cash equivalents$32,400 $25,427 
Short-term investments4,734 4,201 
Accounts receivable, net20,024 21,276 
Other current receivables, net27,461 17,694 
Assets under management— 3,755 
Prepaid expenses and other current assets7,639 6,084 
Total current assets92,258 78,437 
Long-term investments48,689 47,609 
Property, equipment and capitalized software, net
10,139 11,450 
Goodwill105,978 103,732 
Other intangible assets, net23,594 15,194 
Other assets18,651 17,298 
Total assets$299,309 $273,720 
Liabilities, redeemable noncontrolling interests and equity
Current liabilities:
Medical costs payable$33,951 $32,395 
Accounts payable and accrued liabilities33,080 31,958 
Short-term borrowings and current maturities of long-term debt3,909 4,274 
Unearned revenues3,320 3,355 
Other current liabilities27,305 27,072 
Total current liabilities101,565 99,054 
Long-term debt, less current maturities74,101 58,263 
Deferred income taxes4,014 3,021 
Other liabilities15,174 14,463 
Total liabilities194,854 174,801 
Redeemable noncontrolling interests4,574 4,498 
Equity:
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding
— — 
Common stock, $0.01 par value - 3,000 shares authorized; 923 and 924 issued and outstanding
9 9 
Additional paid-in capital461 — 
Retained earnings96,518 95,774 
Accumulated other comprehensive loss(2,453)(7,027)
Nonredeemable noncontrolling interests
5,346 5,665 
Total equity99,881 94,421 
Total liabilities, redeemable noncontrolling interests and equity$299,309 $273,720 
1
UnitedHealth Group
Condensed Consolidated Statements of Operations
(Unaudited)
 Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions, except per share data)2024202320242023
Revenues:
Premiums$77,442 $72,339 $232,327 $217,599 
Products12,631 10,354 36,751 31,272 
Services9,104 8,671 26,742 25,414 
Investment and other income1,643 997 3,651 2,910 
Total revenues100,820 92,361 299,471 277,195 
Operating costs:
Medical costs65,957 59,550 197,150 179,663 
Operating costs13,280 13,855 40,519 41,289 
Cost of products sold11,834 9,423 34,230 28,576 
Depreciation and amortization1,041 1,007 3,058 2,998 
Total operating costs92,112 83,835 274,957 252,526 
Earnings from operations8,708 8,526 24,514 24,669 
Interest expense(1,074)(834)(2,903)(2,416)
Loss on sale of subsidiary and subsidiaries held for sale(20)— (8,331)— 
Earnings before income taxes7,614 7,692 13,280 22,253 
Provision for income taxes(1,356)(1,654)(3,822)(4,784)
Net earnings6,258 6,038 9,458 17,469 
Earnings attributable to noncontrolling interests(203)(197)(596)(543)
Net earnings attributable to UnitedHealth Group common shareholders$6,055 $5,841 $8,862 $16,926 
Earnings per share attributable to UnitedHealth Group common shareholders:
Basic$6.56 $6.31 $9.61 $18.20 
Diluted$6.51 $6.24 $9.53 $18.01 
Basic weighted-average number of common shares outstanding923 926 922 930 
Dilutive effect of common share equivalents7 10 8 10 
Diluted weighted-average number of common shares outstanding930 936 930 940 
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents4 6 6 6 
2
UnitedHealth Group
Condensed Consolidated Statements of Comprehensive Income
(Unaudited)
 Three Months Ended
September 30,		Nine Months Ended
September 30,
(in millions)2024202320242023
Net earnings$6,258 $6,038 $9,458 $17,469 
Other comprehensive income (loss):
Gross unrealized gains (losses) on investment securities during the period1,434 (893)1,069 (684)
Income tax effect(328)204 (243)156 
Total unrealized gains (losses), net of tax1,106 (689)826 (528)
Gross reclassification adjustment for net realized (gains) losses included in net earnings(291)7 (349)(27)
Income tax effect67 (2)80 6 
Total reclassification adjustment, net of tax
(224)5 (269)(21)
Foreign currency translation gains (losses) 88 (354)(197)254 
Reclassification adjustment for translation losses included in net earnings— — 4,214 — 
Total foreign currency translation gains (losses)88 (354)4,017 254 
Other comprehensive income (loss)970 (1,038)4,574 (295)
Comprehensive income7,228 5,000 14,032 17,174 
Comprehensive income attributable to noncontrolling interests(203)(197)(596)(543)
Comprehensive income attributable to UnitedHealth Group common shareholders$7,025 $4,803 $13,436 $16,631 
3
UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common StockAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive LossNonredeemable Noncontrolling InterestsTotal
Equity
Three months ended September 30,
(in millions)		SharesAmountNet Unrealized (Losses) Gains on InvestmentsForeign Currency Translation (Losses) Gains
Balance at June 30, 2024921 $9 $373 $92,400 $(2,296)$(1,127)$5,317 $94,676 
Net earnings6,055 155 6,210 
Other comprehensive income882 88 970 
Issuances of common stock, and related tax effects
4 — 842 842 
Share-based compensation
208 208 
Common share repurchases(2)— (957)— (957)
Cash dividends paid on common shares ($2.10 per share)
(1,937)(1,937)
Redeemable noncontrolling interests fair value and other adjustments
(5)(5)
Acquisition and other adjustments of nonredeemable noncontrolling interests
28 28 
Distribution to nonredeemable noncontrolling interests
(154)(154)
Balance at September 30, 2024923 $9 $461 $96,518 $(1,414)$(1,039)$5,346 $99,881 
Balance at June 30, 2023927 $9 $— $89,994 $(2,643)$(5,007)$5,015 $87,368 
Net earnings
5,841 149 5,990 
Other comprehensive loss(684)(354)(1,038)
Issuances of common stock, and related tax effects
1 — 395 395 
Share-based compensation
235 235 
Common share repurchases(3)— (588)(923)(1,511)
Cash dividends paid on common shares ($1.88 per share)
(1,739)(1,739)
Redeemable noncontrolling interests fair value and other adjustments
(42)(42)
Acquisition and other adjustments of nonredeemable noncontrolling interests42 42 
Distribution to nonredeemable noncontrolling interests
(136)(136)
Balance at September 30, 2023925 $9 $— $93,173 $(3,327)$(5,361)$5,070 $89,564 







4
UnitedHealth Group
Condensed Consolidated Statements of Changes in Equity
(Unaudited)
Common StockAdditional Paid-In CapitalRetained EarningsAccumulated Other Comprehensive LossNonredeemable Noncontrolling InterestsTotal
Equity
Nine months ended September 30,
(in millions)		SharesAmountNet Unrealized (Losses) Gains on InvestmentsForeign Currency Translation (Losses) Gains
Balance at January 1, 2024924 $9 $— $95,774 $(1,971)$(5,056)$5,665 $94,421 
Net earnings8,862 462 9,324 
Other comprehensive income557 4,017 4,574 
Issuances of common stock, and related tax effects7 — 1,280 1,280 
Share-based compensation770 770 
Common share repurchases(8)— (1,528)(2,517)(4,045)
Cash dividends paid on common shares ($6.08 per share)
(5,601)(5,601)
Redeemable noncontrolling interests fair value and other adjustments(61)(61)
Acquisition and other adjustments of nonredeemable noncontrolling interests(291)(291)
Distribution to nonredeemable noncontrolling interests(490)(490)
Balance at September 30, 2024923 $9 $461 $96,518 $(1,414)$(1,039)$5,346 $99,881 
Balance at January 1, 2023934 $9 $— $86,156 $(2,778)$(5,615)$3,678 $81,450 
Net earnings
16,926 401 17,327 
Other comprehensive (loss) income(549)254 (295)
Issuances of common stock, and related tax effects
4 — 963 963 
Share-based compensation
833 833 
Common share repurchases(13)— (1,663)(4,886)(6,549)
Cash dividends paid on common shares ($5.41 per share)
(5,023)(5,023)
Redeemable noncontrolling interests fair value and other adjustments
(133)(133)
Acquisition and other adjustments of nonredeemable noncontrolling interests1,339 1,339 
Distribution to nonredeemable noncontrolling interests
(348)(348)
Balance at September 30, 2023925 $9 $— $93,173 $(3,327)$(5,361)$5,070 $89,564 
5
UnitedHealth Group
Condensed Consolidated Statements of Cash Flows
(Unaudited)
 Nine Months Ended
September 30,
(in millions)20242023
Operating activities
Net earnings$9,458 $17,469 
Noncash items:
Depreciation and amortization3,058 2,998 
Deferred income taxes(234)(494)
Share-based compensation831 851 
Loss on sale of subsidiary and subsidiaries held for sale8,331 — 
Other, net(610)(59)
Net change in other operating items, net of effects from acquisitions and dispositions:
Accounts receivable685 (2,574)
Other assets(2,988)(2,358)
Medical costs payable2,235 3,837 
Accounts payable and other liabilities1,250 2,370 
Unearned revenues(181)12,221 
Cash flows from operating activities21,835 34,261 
Investing activities
Purchases of investments(19,951)(12,998)
Sales of investments15,065 3,674 
Maturities of investments6,738 6,474 
Cash paid for acquisitions and other transactions, net of cash assumed(11,674)(8,389)
Purchases of property, equipment and capitalized software(2,587)(2,427)
Loans to care providers - cyberattack(8,904)— 
Repayments of care provider loans - cyberattack3,189 — 
Other, net(1,284)(721)
Cash flows used for investing activities(19,408)(14,387)
Financing activities
Common share repurchases(4,028)(6,500)
Cash dividends paid(5,601)(5,023)
Proceeds from common stock issuances1,611 1,039 
Repayments of long-term debt(2,500)(2,125)
(Repayments of) proceeds from short-term borrowings, net(191)1,579 
Proceeds from issuance of long-term debt17,811 6,394 
Customer funds administered(1,059)2,037 
Other, net(1,213)(1,774)
Cash flows from (used for) financing activities4,830 (4,373)
Effect of exchange rate changes on cash and cash equivalents(30)49 
Increase in cash and cash equivalents, including cash within businesses held for sale7,227 15,550 
Less: cash within businesses held for sale(254)— 
Net increase in cash and cash equivalents6,973 15,550 
Cash and cash equivalents, beginning of period25,427 23,365 
Cash and cash equivalents, end of period$32,400 $38,915 
6
UnitedHealth Group
Notes to the Condensed Consolidated Financial Statements
(Unaudited)
1.    Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. The Company’s two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC (2023 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
Revenues - Products and Services
As of September 30, 2024 and December 31, 2023, accounts receivable related to products and services were $9.2 billion and $8.6 billion, respectively. As of September 30, 2024, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $13.0 billion, of which approximately half is expected to be recognized in the next three years.
Assets Under Management
In July 2024, the Company amended and restated its Medicare Supplement Program with a membership organization (the Medicare Supplement Program). The amendments provide the Company the right to use a trade name and other intellectual property in marketing efforts for Medicare Supplement offerings. Amounts previously reported as assets under management are now included within the Company’s Condensed Consolidated Balance Sheet based upon their classification.
For periods prior to the amended and restated Medicare Supplement Program, the Company excluded the effects of certain balance sheet amounts in its Condensed Consolidated Statements of Cash Flows, while these effects are included for periods after the amendments.
7
2.    Investments
A summary of debt securities by major security type is as follows:
(in millions)Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
September 30, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations$5,005 $5 $(182)$4,828 
State and municipal obligations7,301 23 (256)7,068 
Corporate obligations23,752 82 (781)23,053 
U.S. agency mortgage-backed securities9,209 21 (600)8,630 
Non-U.S. agency mortgage-backed securities2,832 6 (154)2,684 
Total debt securities - available-for-sale48,099 137 (1,973)46,263 
Debt securities - held-to-maturity:
U.S. government and agency obligations414 1 (2)413 
State and municipal obligations28 — (2)26 
Corporate obligations22 — — 22 
Total debt securities - held-to-maturity464 1 (4)461 
Total debt securities$48,563 $138 $(1,977)$46,724 
December 31, 2023
Debt securities - available-for-sale:
U.S. government and agency obligations$4,674 $3 $(234)$4,443 
State and municipal obligations7,636 39 (322)7,353 
Corporate obligations23,136 67 (1,186)22,017 
U.S. agency mortgage-backed securities8,982 22 (708)8,296 
Non-U.S. agency mortgage-backed securities3,023 3 (240)2,786 
Total debt securities - available-for-sale47,451 134 (2,690)44,895 
Debt securities - held-to-maturity:
U.S. government and agency obligations506 1 (6)501 
State and municipal obligations28 — (2)26 
Corporate obligations69 — — 69 
Total debt securities - held-to-maturity603 1 (8)596 
Total debt securities$48,054 $135 $(2,698)$45,491 
The Company held $4.9 billion of equity securities as of September 30, 2024 and December 31, 2023. The Company’s investments in equity securities primarily consist of venture investments and employee savings plan related investments. Additionally, the Company’s investments included $1.8 billion and $1.4 billion of equity method investments primarily in operating businesses in the health care sector as of September 30, 2024 and December 31, 2023, respectively. The allowance for credit losses on held-to-maturity securities at September 30, 2024 and December 31, 2023 was not material.
8
The amortized cost and fair value of debt securities as of September 30, 2024, by contractual maturity, were as follows:
Available-for-SaleHeld-to-Maturity
(in millions)Amortized
Cost		Fair
Value		Amortized
Cost		Fair
Value
Due in one year or less$4,881 $4,861 $320 $319 
Due after one year through five years15,152 14,810 113 114 
Due after five years through ten years10,993 10,432 14 13 
Due after ten years5,032 4,846 17 15 
U.S. agency mortgage-backed securities9,209 8,630 — — 
Non-U.S. agency mortgage-backed securities2,832 2,684 — — 
Total debt securities$48,099 $46,263 $464 $461 
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:
 Less Than 12 Months12 Months or Greater Total
(in millions)Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses
September 30, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations
$894 $(7)$2,448 $(175)$3,342 $(182)
State and municipal obligations726 (6)4,278 (250)5,004 (256)
Corporate obligations3,499 (18)12,174 (763)15,673 (781)
U.S. agency mortgage-backed securities2,140 (20)5,018 (580)7,158 (600)
Non-U.S. agency mortgage-backed securities
138 (1)1,990 (153)2,128 (154)
Total debt securities - available-for-sale$7,397 $(52)$25,908 $(1,921)$33,305 $(1,973)
December 31, 2023
Debt securities - available-for-sale:
U.S. government and agency obligations
$1,270 $(7)$2,077 $(227)$3,347 $(234)
State and municipal obligations907 (7)4,063 (315)4,970 (322)
Corporate obligations1,826 (17)14,696 (1,169)16,522 (1,186)
U.S. agency mortgage-backed securities1,337 (12)5,069 (696)6,406 (708)
Non-U.S. agency mortgage-backed securities
279 (6)2,202 (234)2,481 (240)
Total debt securities - available-for-sale$5,619 $(49)$28,107 $(2,641)$33,726 $(2,690)
The Company’s unrealized losses from debt securities as of September 30, 2024 were generated from approximately 27,000 positions out of a total of 41,000 positions. The Company believes that it will timely collect the principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of September 30, 2024, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities at September 30, 2024 and December 31, 2023 was not material.
9
3.    Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2023 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)		Total
Fair and Carrying
Value
September 30, 2024
Cash and cash equivalents$32,230$170$—$32,400
Debt securities - available-for-sale:
U.S. government and agency obligations4,682146—4,828
State and municipal obligations—7,068—7,068
Corporate obligations2722,71930723,053
U.S. agency mortgage-backed securities—8,630—8,630
Non-U.S. agency mortgage-backed securities—2,684—2,684
Total debt securities - available-for-sale4,70941,24730746,263
Equity securities1,83325651,923
Total assets at fair value$38,772$41,442$372$80,586
Percentage of total assets at fair value48 %51 %1 %100 %
December 31, 2023
Cash and cash equivalents$25,345$82$—$25,427
Debt securities - available-for-sale:
U.S. government and agency obligations4,167276—4,443
State and municipal obligations—7,353—7,353
Corporate obligations1521,80020222,017
U.S. agency mortgage-backed securities—8,296—8,296
Non-U.S. agency mortgage-backed securities—2,786—2,786
Total debt securities - available-for-sale4,18240,51120244,895
Equity securities2,46816692,553
Assets under management 1,5052,1401103,755
Total assets at fair value$33,500$42,749$381$76,630
Percentage of total assets at fair value44 %55 %1 %100 %
There were no transfers in or out of Level 3 financial assets or liabilities during the nine months ended September 30, 2024 or 2023.
10
The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)		Total
Fair
Value		Total Carrying Value
September 30, 2024
Debt securities - held-to-maturity$435 $26 $— $461 $464 
Long-term debt and other financing obligations$— $75,798 $— $75,798 $76,780 
December 31, 2023
Debt securities - held-to-maturity$524 $72 $— $596 $603 
Long-term debt and other financing obligations$— $59,851 $— $59,851 $61,449 
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. The assets and liabilities within our South American operations held for sale as of September 30, 2024 were measured at the lower of carrying value or fair value less cost to sell. Fair value is measured based upon unobservable amounts, such as estimated selling price derived from Company-specific information and market conditions. There were no other significant fair value adjustments for assets and liabilities recorded during the nine months ended September 30, 2024 or 2023.
4.    Medical Costs Payable
The following table shows the components of the change in medical costs payable for the nine months ended September 30:
(in millions)20242023
Medical costs payable, beginning of period$32,395 $29,056 
Acquisitions (dispositions), net(755)1 
Reported medical costs:
Current year197,750 180,423 
Prior years(600)(760)
Total reported medical costs197,150 179,663 
Medical payments:
Payments for current year
(165,544)(149,671)
Payments for prior years(29,095)(26,257)
Total medical payments(194,639)(175,928)
Less: medical costs payable included within businesses held for sale(200)— 
Medical costs payable, end of period$33,951 $32,792 
For the nine months ended September 30, 2024 and 2023, prior years’ medical cost reserve development included no individual factors that were significant. Medical costs payable included reserves for claims incurred by consumers but not yet reported to the Company of $24.1 billion and $22.3 billion at September 30, 2024 and December 31, 2023, respectively.
11
5.    Short-Term Borrowings and Long-Term Debt
In March 2024, the Company issued $6.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages)Par Value
4.600% notes due April 2027
$500 
4.700% notes due April 2029
400 
4.900% notes due April 2031
1,000 
5.000% notes due April 2034
1,250 
5.375% Notes due April 2054
1,750 
5.500% Notes due April 2064
1,100 
In July 2024, the Company issued $12.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages)Par Value
Floating rate notes due July 2026
$500 
4.750% notes due July 2026
650 
4.800% notes due January 2030
1,250 
4.950% notes due January 2032
1,500 
5.150% notes due July 2034
2,000 
5.500% notes due July 2044
1,500 
5.625% notes due July 2054
2,750 
5.750% notes due July 2064
1,850 
As of September 30, 2024, the Company had $1.2 billion of commercial paper outstanding, with a weighted-average annual interest rate of 5.4%.
In May 2024, the Company entered into an additional $3 billion 364-day revolving bank credit facility and a $5 billion 364-day delayed draw term loan. The $5 billion 364-day delayed draw term loan was terminated in September 2024. As of September 30, 2024 no amount had been drawn on any of the bank credit facilities.
For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2023 10-K.
6.    Other Intangible Assets
The fair values and weighted-average useful lives assigned to intangible assets as a result of transactions completed during the nine months ended September 30, 2024 consisted of the following:
(in millions, except years)Fair ValueWeighted-Average Useful Life
Customer-related$1,070 13 years
Trademarks and technology509 5 years
Other20 8 years
Total finite-lived$1,599 11 years
Total indefinite-lived - trade names, trademarks, operating licenses and certificates and other8,793 
Total intangible assets$10,392 
12
7.    Shareholders’ Equity
Share Repurchase Program
In June 2024, the Company’s Board of Directors amended the Company’s share repurchase program to authorize the repurchase of up to 35 million shares of Common Stock, in addition to all remaining shares authorized to be repurchased under the Board’s 2018 renewal of the program. As of September 30, 2024, the Company had 42 million shares remaining available under its share repurchase authorization.
Dividends
In June 2024, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual rate of $8.40 compared to $7.52 per share, which the Company had paid since June 2023. Declaration and payment of future quarterly dividends is at the discretion of the Board of Directors and may be adjusted as business needs or market conditions change.
The following table provides details of the Company’s dividend payments during the nine months ended September 30, 2024:
Payment DateAmount per ShareTotal Amount Paid
(in millions)
March 19$1.88 $1,729 
June 252.10 1,935 
September 242.10 1,937 
8.    Commitments and Contingencies
Pending Transactions
As of September 30, 2024, the Company had entered into transaction agreements in the health care sector, subject to regulatory approval and/or other customary closing conditions. The total anticipated consideration required for these transactions, excluding the payoff of acquired indebtedness, was approximately $5 billion.
Legal Matters
The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office for Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Consumer Financial Protection Bureau, the Defense Contract Audit Agency, the Food and Drug Administration and other governmental authorities. Similarly, the Company’s international businesses are also subject to investigations, audits and reviews by applicable foreign governments. The Company has also been responding to subpoenas, information requests and investigations from governmental entities. The Company can provide no assurance as to the scope and outcome of these matters and no assurance as to whether its business, financial condition or results of operations will be materially adversely affected. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the
13
Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans.
On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, the DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.
9.    Dispositions and Held for Sale
During the nine months ended September 30, 2024, the Company completed or initiated various business portfolio and asset disposition activities. The Company recorded a loss of $7.1 billion related to the sale of its Brazil operations, of which $4.1 billion related to the impact of cumulative foreign currency translation losses previously included in accumulated other comprehensive loss, and a loss of $1.2 billion related to the reclassification of the Company’s remaining South American operations as held for sale, of which $876 million related to the impact of cumulative foreign currency translation losses.
The Company also sold other businesses and assets for $1.0 billion in total consideration, with a carrying value of $241 million, and the difference reflected in the Condensed Consolidated Statement of Operations. The sales of the Company’s remaining South American assets are expected to close within a year, subject to regulatory and other customary closing conditions. Assets and liabilities held for sale have been included within prepaid and other current assets and other current liabilities on the Condensed Consolidated Balance Sheet, respectively.
The assets and liabilities of the Brazil and held for sale disposal groups as of the date of the sale and as of September 30, 2024, respectively, were as follows:
(in millions)Brazil
Disposition		Businesses
Held for Sale
Assets
Cash and cash equivalents$778 $254 
Accounts receivable and other current assets515 652 
Long-term investments788 36 
Property, equipment and capitalized software1,052 674 
Deferred tax assets1,035 — 
Goodwill and other intangible assets317 450 
Other long-term assets439 253 
Remeasurement of assets of businesses held for sale to fair value less cost to sell(1)
— (1,245)
Total assets$4,924 $1,074 
Liabilities
Medical costs payable$701 $200 
Accounts payable and other current liabilities834 395 
Other long-term liabilities136 544 
Total liabilities$1,671 $1,139 
(1)      Includes the effect of $876 million of cumulative foreign currency translation losses and $54 million of noncontrolling interests.
14
10.    Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more information on the Company’s segments, see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2023 10-K.
The following tables present reportable segment financial information:
  Optum  
(in millions)UnitedHealthcareOptum HealthOptum InsightOptum RxOptum EliminationsOptumCorporate and
Eliminations		Consolidated
Three Months Ended September 30, 2024
Revenues - unaffiliated customers:
Premiums$71,624 $5,818 $— $— $— $5,818 $— $77,442 
Products— 84 41 12,506 — 12,631 — 12,631 
Services2,422 3,953 1,700 1,029 — 6,682 — 9,104 
Total revenues - unaffiliated customers
74,046 9,855 1,741 13,535 — 25,131 — 99,177 
Total revenues - affiliated customers
— 15,448 3,086 20,554 (1,130)37,958 (37,958)— 
Investment and other income
807 614 104 118 — 836 — 1,643 
Total revenues$74,853 $25,917 $4,931 $34,207 $(1,130)$63,925 $(37,958)$100,820 
Earnings from operations$4,212 $2,161 $791 $1,544 $— $4,496 $— $8,708 
Interest expense— — — — — — (1,074)(1,074)
Loss on sale of subsidiary and subsidiaries held for sale(20)— — — — — — (20)
Earnings before income taxes
$4,192 $2,161 $791 $1,544 $— $4,496 $(1,074)$7,614 
Three Months Ended September 30, 2023
Revenues - unaffiliated customers:
Premiums$66,709 $5,630 $— $— $— $5,630 $— $72,339 
Products— 61 40 10,253 — 10,354 — 10,354 
Services2,550 3,629 1,938 554 — 6,121 — 8,671 
Total revenues - unaffiliated customers
69,259 9,320 1,978 10,807 — 22,105 — 91,364 
Total revenues - affiliated customers
— 14,227 2,964 17,999 (961)34,229 (34,229)— 
Investment and other income
594 317 35 51 — 403 — 997 
Total revenues$69,853 $23,864 $4,977 $28,857 $(961)$56,737 $(34,229)$92,361 
Earnings from operations$4,592 $1,568 $1,109 $1,257 $— $3,934 $— $8,526 
Interest expense— — — — — — (834)(834)
Earnings before income taxes
$4,592 $1,568 $1,109 $1,257 $— $3,934 $(834)$7,692 
15
  Optum  
(in millions)UnitedHealthcareOptum HealthOptum InsightOptum RxOptum EliminationsOptumCorporate and
Eliminations		Consolidated
Nine Months Ended September 30, 2024
Revenues - unaffiliated customers:
Premiums$214,867 $17,460 $— $— $— $17,460 $— $232,327 
Products— 205 123 36,423 — 36,751 — 36,751 
Services7,339 12,006 4,807 2,590 — 19,403 — 26,742 
Total revenues - unaffiliated customers
222,206 29,671 4,930 39,013 — 73,614 — 295,820 
Total revenues - affiliated customers
— 48,641 8,887 58,208 (3,275)112,461 (112,461)— 
Investment and other income
1,870 1,386 159 236 — 1,781 — 3,651 
Total revenues$224,076 $79,698 $13,976 $97,457 $(3,275)$187,856 $(112,461)$299,471 
Earnings from operations$12,611 $5,979 $1,827 $4,097 $— $11,903 $— $24,514 
Interest expense— — — — — — (2,903)(2,903)
Loss on sale of subsidiary and subsidiaries held for sale(8,331)— — — — — — (8,331)
Earnings before income taxes
$4,280 $5,979 $1,827 $4,097 $— $11,903 $(2,903)$13,280 
Nine Months Ended September 30, 2023
Revenues - unaffiliated customers:
Premiums$201,214 $16,385 $— $— $— $16,385 $— $217,599 
Products— 156 119 30,997 — 31,272 — 31,272 
Services7,689 10,259 5,859 1,607 — 17,725 — 25,414 
Total revenues - unaffiliated customers
208,903 26,800 5,978 32,604 — 65,382 — 274,285 
Total revenues - affiliated customers
— 42,947 8,089 52,174 (2,713)100,497 (100,497)— 
Investment and other income
1,649 1,038 80 143 — 1,261 — 2,910 
Total revenues$210,552 $70,785 $14,147 $84,921 $(2,713)$167,140 $(100,497)$277,195 
Earnings from operations$13,293 $4,869 $2,984 $3,523 $— $11,376 $— $24,669 
Interest expense— — — — — — (2,416)(2,416)
Earnings before income taxes
$13,293 $4,869 $2,984 $3,523 $— $11,376 $(2,416)$22,253 
16
ITEM 2.    MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
The following discussion should be read together with the accompanying Condensed Consolidated Financial Statements and Notes and with our 2023 10-K, including the Consolidated Financial Statements and Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in that report. Unless the context indicates otherwise, references to the terms “UnitedHealth Group,” the “Company,” “we,” “our” or “us” used throughout this Management’s Discussion and Analysis of Financial Condition and Results of Operations refer to UnitedHealth Group Incorporated and its consolidated subsidiaries.
Readers are cautioned that the statements, estimates, projections or outlook contained in this Management's Discussion and Analysis of Financial Condition and Results of Operations, including discussions regarding financial prospects, economic conditions, trends and uncertainties contained in this Item 2, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve risks and uncertainties that may cause our actual results to differ materially from the results discussed or implied in the forward-looking statements. A description of some of the risks and uncertainties is set forth in Part I, Item 1A, “Risk Factors” in our 2023 10-K and in the discussion below.
EXECUTIVE OVERVIEW
General
UnitedHealth Group is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. Our two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations we are privileged to serve.
We have four reportable segments:
•Optum Health;
•Optum Insight;
•Optum Rx; and
•UnitedHealthcare, which includes UnitedHealthcare Employer & Individual, UnitedHealthcare Medicare & Retirement and UnitedHealthcare Community & State.
Further information on our business is presented in Part I, Item 1, “Business” and Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2023 10-K and additional information on our segments can be found in this Item 2 and in Note 10 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Change Healthcare Cyberattack
As previously announced, on February 21, 2024, we identified that cybercrime threat actors had gained access to certain Change Healthcare information technology systems. Upon detection of this outside threat, we isolated the impacted systems to protect our partners and customers.
We have made substantial progress in mitigating the impact to consumers and care providers of the unprecedented cyberattack on the U.S. health system and have restored the majority of the affected Change Healthcare services. To support care providers we provided interest-free loans of nearly $9 billion through September 30, 2024. For the three and nine months ended September 30, 2024, we incurred $341 million and $1.7 billion of direct response costs, respectively; including increased medical care expenditures, as we suspended some care management activities to help care providers with their workflow processes; costs associated with providing interest-free loans; notifications of impacted persons; and network restoration. Optum Insight also experienced estimated business disruption impacts of $134 million and $747 million for the three and nine months ended September 30, 2024, respectively, reflecting lost revenue while maintaining full readiness of the affected Change Healthcare services. We expect to continue to incur direct response costs and experience business disruption impacts over the remainder of the year, which will continue at a lesser extent in 2025 as we work to bring transaction volumes back to pre-event levels and win new business.
Based upon our ongoing review of the impacted data, we have found files containing protected health information (PHI) or personally identifiable information (PII), which cover a substantial proportion of people in America. In June 2024, Change Healthcare gave public notice of the breach under the Health Insurance Portability and Accountability Act (HIPAA) and began notifying affected customer entities in June and individuals in late July. The investigation of impacted data is ongoing. It is
17
possible that future risks and uncertainties resulting from the Change Healthcare cyberattack, including risks related to impacted data, litigation, reputational harm, and regulatory actions could adversely affect our financial condition or results of operations.
Business Trends
Our businesses participate in the United States and certain other international health markets. We expect overall spending on health care to continue to grow in the future, due to inflation, medical technology and pharmaceutical advancement, regulatory requirements, demographic trends in the population and national interest in health and well-being. The rate of market growth may be affected by a variety of factors, including macroeconomic conditions and regulatory changes, which could impact our results of operations, including our continued efforts to control health care costs.
Pricing Trends. To price our health care benefits, products and services, we start with our view of expected future costs, including medical cost trends, inflation and labor market dynamics. We frequently evaluate and adjust our approach in each of the local markets we serve, considering all relevant factors, such as product positioning, price competitiveness and environmental, competitive, legislative and regulatory considerations, including minimum medical loss ratio thresholds and similar revenue adjustments. We will continue seeking to balance growth and profitability across all these dimensions.
The commercial risk market remains highly competitive in the small group, large group and individual segments. We expect broad-based competition to continue as the industry adapts to individual and employer needs.
Government programs in the community and senior sector tend to receive lower rates of increase than the commercial market due to governmental budget pressures and lower cost trends.
Medical Cost Trends. Our medical cost trends primarily relate to changes in unit costs, care activity and prescription drug costs. As expected and contemplated in our benefits design, we have continued to observe increased care patterns, primarily related to outpatient procedures for seniors, which may continue in future periods. In the third quarter, we also experienced higher medical costs due to a pronounced upshift in coding intensity by hospitals and an acceleration of the prescribing of certain high-cost specialty medications, primarily those used to treat cardiovascular disease, auto-immune disorders and cancer. We endeavor to mitigate these increases by engaging hospitals, physicians and consumers with information and helping them make clinically sound choices, with the objective of helping them achieve quality, affordable care.
As a result of the Change Healthcare cyberattack, we incurred medical costs related to the impact of the temporary suspension of some care management activities, impacting our UnitedHealthcare and Optum Health businesses, to help care providers with their workflow processes. Early in the second quarter we resumed these activities. For the nine months ended September 30, 2024, medical costs related to the temporary suspension of some care management activities were $630 million.
Medicaid Redeterminations. Medicaid redeterminations have impacted the number of people served through our Medicaid offerings, partially offset by an increase in consumers served through our commercial offerings as we endeavor to ensure that people and families have continued access to care. The Medicaid redetermination process has also caused a timing mismatch between the current health status of people served through Medicaid and state rate updates, which remain well short of current care activity.
Regulatory Trends and Uncertainties
Medicare Advantage Rates. Medicare Advantage rate notices over the years have at times resulted in industry base rates well below the industry forward medical cost trend. For example, the Final Notices for 2024 and 2025 rates resulted in an industry base rate decrease, both well short of an increasing industry forward medical cost trend, creating continued pressure in the Medicare Advantage program. Further, substantial revisions to the risk adjustment model, which serves to adjust rates to reflect a patient’s health status and care resource needs, will result in reduced funding and potentially benefits for people, especially those with some of the greatest health and social challenges.
As a result of ongoing Medicare funding pressures, there are adjustments we can make to partially offset these rate pressures and reductions for a particular period. For example, we can seek to intensify our medical and operating cost management, make changes to the size and composition of our care provider networks, adjust member benefits and implement or increase the member premiums supplementing the monthly payments we receive from the government. Additionally, we decide annually on a county-by-county basis where we will offer Medicare Advantage plans.
18
SELECTED OPERATING PERFORMANCE AND OTHER SIGNIFICANT ITEMS
The following summarizes select third quarter 2024 year-over-year operating comparisons to third quarter 2023 and other financial results.
•Consolidated revenues grew 9%, UnitedHealthcare revenues grew 7% and Optum revenues grew 13%.
•UnitedHealthcare served 2.0 million more people domestically, driven by growth in commercial offerings, partially offset by the impact of Medicaid redeterminations.
•Consolidated earnings from operations of $8.7 billion compared to $8.5 billion last year.
•Diluted earnings per common share was $6.51.
•Cash flows from operations for the nine months ended September 30, 2024 were $21.8 billion.
RESULTS SUMMARY
The following table summarizes our consolidated results of operations and other financial information:
(in millions, except percentages and per share data)Three Months Ended
September 30,		Increase/
(Decrease)		Nine Months Ended
September 30,		Increase/
(Decrease)
202420232024 vs. 2023202420232024 vs. 2023
Revenues:
Premiums$77,442 $72,339$5,103 7 %$232,327 $217,599$14,728 7 %
Products12,631 10,3542,277 22 36,751 31,2725,479 18 
Services9,104 8,671433 5 26,742 25,4141,328 5 
Investment and other income1,643 997646 65 3,651 2,910741 25 
Total revenues100,820 92,3618,459 9 299,471 277,19522,276 8 
Operating costs:
Medical costs65,957 59,5506,407 11 197,150 179,66317,487 10 
Operating costs13,280 13,855(575)(4)40,519 41,289(770)(2)
Cost of products sold11,834 9,4232,411 26 34,230 28,5765,654 20 
Depreciation and amortization1,041 1,00734 3 3,058 2,99860 2 
Total operating costs92,112 83,8358,277 10 274,957 252,52622,431 9 
Earnings from operations8,708 8,526182 2 24,514 24,669(155)(1)
Interest expense(1,074)(834)(240)29 (2,903)(2,416)(487)20 
Loss on sale of subsidiary and subsidiaries held for sale(20)—(20)nm(8,331)—(8,331)nm
Earnings before income taxes7,614 7,692(78)(1)13,280 22,253(8,973)(40)
Provision for income taxes(1,356)(1,654)298 (18)(3,822)(4,784)962 (20)
Net earnings6,258 6,038220 4 9,458 17,469(8,011)(46)
Earnings attributable to noncontrolling interests(203)(197)(6)3 (596)(543)(53)10 
Net earnings attributable to UnitedHealth Group common shareholders$6,055 $5,841$214 4 $8,862 $16,926$(8,064)(48)
Diluted earnings per share attributable to UnitedHealth Group common shareholders $6.51 $6.24$0.27 $9.53 $18.01$(8.48)
Medical care ratio (a)85.2 %82.3%2.9 %84.9 %82.6%2.3 %
Operating cost ratio13.2 15.0(1.8)13.5 14.9(1.4)
Operating margin8.6 9.2(0.6)8.2 8.9(0.7)
Tax rate17.8 21.5(3.7)28.8 21.57.3 
Net earnings margin (b)6.0 6.3(0.3)3.0 6.1(3.1)
Return on equity (c)26.3%28.0%(1.7)13.2%27.7%(14.5)
nm = not meaningful
(a)Medical care ratio (MCR) is calculated as medical costs divided by premium revenue.
(b)Net earnings margin attributable to UnitedHealth Group shareholders.
(c)Return on equity is calculated as annualized net earnings attributable to UnitedHealth Group common shareholders divided by average shareholders’ equity. Average shareholders’ equity is calculated using the shareholders’ equity balance at the end of the preceding year and the shareholders’ equity balances at the end of each of the quarters in the year presented.
19
2024 RESULTS OF OPERATIONS COMPARED TO 2023 RESULTS OF OPERATIONS
Consolidated Financial Results
Revenues
The increases in revenues were primarily driven by growth in Optum Rx and Optum Health, growth across our UnitedHealthcare domestic offerings and pricing trends, partially offset by decreased UnitedHealthcare international revenue due to the sale of our Brazil operations.
Medical Costs and MCR
Medical costs increased primarily due to growth in people served through Medicare Advantage, those with higher acuity needs and domestic commercial offerings. The MCR increased as a result of the revenue effects of the Medicare funding reductions, decreased favorable reserve development and member mix. For the nine months ended September 30, 2024, the MCR also increased due to incremental medical costs for accommodations made to care providers as a result of the Change Healthcare cyberattack.
Operating Cost Ratio
The operating cost ratio decreased primarily due to operating cost management and business portfolio and asset dispositions, partially offset by the impact of our direct response efforts to the Change Healthcare cyberattack and investments to support future growth.
Loss on Sale of Subsidiary and Subsidiaries Held for Sale
On February 6, 2024, the Company completed the sale of its Brazil operations. During the nine months ended September 30, 2024, we recorded a loss of $7.1 billion, of which $4.1 billion related to the impact of cumulative foreign currency translation losses previously included in accumulated other comprehensive loss.
In the second quarter of 2024, the Company initiated a plan to sell its remaining South American operations, which were classified as held for sale as of September 30, 2024. As a result, the Company recorded a loss of $1.2 billion, of which $876 million related to the impact of cumulative foreign currency translation losses.
Reportable Segments
See Note 10 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report for more information on our segments. We utilize various metrics to evaluate and manage our reportable segments, including people served by UnitedHealthcare by major market segment and funding arrangement, people served by Optum Health and adjusted scripts for Optum Rx. These metrics are the main drivers of revenue, earnings and cash flows at each business. The metrics also allow management and investors to evaluate and understand business mix, including the level and scope of services provided to people, and pricing trends when comparing the metrics to revenue by segment.
20
The following table presents a summary of the reportable segment financial information:
 Three Months Ended September 30,Increase/
(Decrease)		Nine Months Ended
September 30,		Increase/
(Decrease)
(in millions, except percentages)202420232024 vs. 2023202420232024 vs. 2023
Revenues
UnitedHealthcare$74,853 $69,853$5,0007 %$224,076$210,552$13,524 6 %
Optum Health25,917 23,8642,0539 79,69870,7858,913 13 
Optum Insight4,931 4,977(46)(1)13,97614,147(171)(1)
Optum Rx34,207 28,8575,35019 97,45784,92112,536 15 
Optum eliminations(1,130)(961)(169)18 (3,275)(2,713)(562)21 
Optum63,925 56,7377,18813 187,856167,14020,716 12 
Eliminations(37,958)(34,229)(3,729)11 (112,461)(100,497)(11,964)12 
Consolidated revenues$100,820 $92,361$8,4599 %$299,471$277,195$22,276 8 %
Earnings from operations
UnitedHealthcare$4,212 $4,592$(380)(8)%$12,611$13,293$(682)(5)%
Optum Health2,161 1,56859338 5,9794,8691,110 23 
Optum Insight791 1,109(318)(29)1,8272,984(1,157)(39)
Optum Rx1,544 1,25728723 4,0973,523574 16 
Optum4,496 3,93456214 11,90311,376527 5 
Consolidated earnings from operations$8,708 $8,526$1822 %$24,514$24,669$(155)(1)%
Operating margin
UnitedHealthcare5.6 %6.6 %(1.0)%5.6 %6.3 %(0.7)%
Optum Health8.3 6.6 1.7 7.5 6.9 0.6 
Optum Insight16.0 22.3 (6.3)13.1 21.1 (8.0)
Optum Rx4.5 4.4 0.1 4.2 4.1 0.1 
Optum7.0 6.9 0.1 6.3 6.8 (0.5)
Consolidated operating margin8.6 %9.2 %(0.6)%8.2 %8.9 %(0.7)%
UnitedHealthcare
The following table summarizes UnitedHealthcare revenues by business:
 Three Months Ended
September 30,		Increase/
(Decrease)		Nine Months Ended
September 30,		Increase/
(Decrease)
(in millions, except percentages)202420232024 vs. 2023202420232024 vs. 2023
UnitedHealthcare Employer & Individual - Domestic$18,985 $16,854 $2,131 13 %$55,470 $50,157 $5,313 11 %
UnitedHealthcare Employer & Individual - Global769 2,417 (1,648)(68)2,892 6,905 (4,013)(58)
UnitedHealthcare Employer & Individual - Total19,754 19,271 483 3 58,362 57,062 1,300 2 
UnitedHealthcare Medicare & Retirement34,904 32,022 2,882 9 105,294 97,468 7,826 8 
UnitedHealthcare Community & State20,195 18,560 1,635 9 60,420 56,022 4,398 8 
Total UnitedHealthcare revenues$74,853 $69,853 $5,000 7 %$224,076 $210,552 $13,524 6 %
21
The following table summarizes the number of people served by our UnitedHealthcare businesses, by major market segment and funding arrangement:
September 30,Increase/(Decrease)
(in thousands, except percentages)202420232024 vs. 2023
Commercial - Domestic:
Risk-based8,900 8,120 780 10 %
Fee-based20,830 19,130 1,700 9 
Total Commercial - Domestic29,730 27,250 2,480 9 
Medicare Advantage7,810 7,645 165 2 
Medicaid7,450 8,065 (615)(8)
Medicare Supplement (Standardized)4,340 4,345 (5)— 
Total Community and Senior19,600 20,055 (455)(2)
Total UnitedHealthcare - Domestic Medical49,330 47,305 2,025 4 
Commercial - Global1,335 5,475 (4,140)(76)
Total UnitedHealthcare - Medical50,665 52,780 (2,115)(4)%
Supplemental Data:
Medicare Part D stand-alone3,055 3,335 (280)(8)%
UnitedHealthcare’s revenues increased due to growth in the number of people served through Medicare Advantage, domestic commercial offerings and those with higher acuity needs, partially offset by decreased people served globally due to the sale of our Brazil operations and Medicaid offerings due to continued redeterminations. Earnings from operations decreased due to Medicare Advantage funding reductions, the impacts of Medicaid redeterminations and decreased favorable reserve development, partially offset by the factors impacting revenue above. For the nine months ended September 30, 2024, earnings from operations also decreased due to incremental medical costs for accommodations to support care providers as a result of the Change Healthcare cyberattack.
Optum
Total revenues increased due to growth at Optum Rx and Optum Health. Earnings from operations increased at Optum Health and Optum Rx, partially offset by the impacts of the Change Healthcare cyberattack. The results by segment were as follows:
Optum Health
Revenues at Optum Health increased primarily due to organic growth in patients served under value-based care arrangements. Earnings from operations increased due to cost management initiatives, business portfolio and asset dispositions and increased investment income, partially offset by Medicare Advantage funding reductions and costs associated with serving newly added patients under value-based care arrangements. Optum Health served approximately 104 million people and 103 million people as of September 30, 2024 and September 30, 2023, respectively.
Optum Insight
Revenues at Optum Insight decreased due the business disruption impacts from the Change Healthcare cyberattack, partially offset by growth in technology services. Earnings from operations decreased primarily due to the business disruption impacts and direct response costs related to the Change Healthcare cyberattack, partially offset by growth in business services.
Optum Rx
Revenues and earnings from operations at Optum Rx increased due to higher script volumes from both new clients and growth in existing clients and growth in pharmacy services. Earnings from operations also increased due to operating cost efficiencies and supply chain initiatives. Optum Rx fulfilled 407 million and 383 million adjusted scripts in the third quarters of 2024 and 2023, respectively.
22
LIQUIDITY, FINANCIAL CONDITION AND CAPITAL RESOURCES
Liquidity
Summary of our Major Sources and Uses of Cash and Cash Equivalents
 Nine Months Ended September 30,Increase/(Decrease)
(in millions)202420232024 vs. 2023
Sources of cash:
Cash provided by operating activities$21,835 $34,261 $(12,426)
Issuances of short-term borrowings and long-term debt, net of repayments15,120 5,848 9,272 
Proceeds from common stock issuances1,611 1,039 572 
Customer funds administered— 2,037 (2,037)
Sales and maturities of investments, net of purchases1,852 — 1,852 
Repayments of care provider loans - cyberattack3,189 — 3,189 
Total sources of cash43,607 43,185 422 
Uses of cash:
Common stock repurchases(4,028)(6,500)2,472 
Cash paid for acquisitions and other transactions, net of cash assumed(11,674)(8,389)(3,285)
Purchases of investments, net of sales and maturities — (2,850)2,850 
Purchases of property, equipment and capitalized software(2,587)(2,427)(160)
Cash dividends paid(5,601)(5,023)(578)
Loans to care providers - cyberattack(8,904)— (8,904)
Customer funds administered(1,059)— (1,059)
Other(2,497)(2,495)(2)
Total uses of cash(36,350)(27,684)(8,666)
Effect of exchange rate changes on cash and cash equivalents(30)49 (79)
Increase in cash and cash equivalents, including cash classified within assets held for sale$7,227 $15,550 $(8,323)
Less: net increase in cash classified within assets held for sale(254)— (254)
Net increase in cash and cash equivalents$6,973 $15,550 $(8,577)
2024 Cash Flows Compared to 2023 Cash Flows
Decreased cash flows provided by operating activities were primarily driven by the receipt of the October CMS premium payment of $11.9 billion in September 2023 and Change Healthcare cyberattack response actions. Other significant changes in sources or uses of cash year-over-year included increased net issuances of short-term borrowings and long-term debt, net sales and maturities of investments and decreased share repurchases, offset by loans to care providers in response to the Change Healthcare cyberattack, increased cash paid for acquisitions and other transactions and decreased customer funds administered.
Financial Condition
As of September 30, 2024, our cash, cash equivalent, available-for-sale debt securities and equity securities balances of $83.5 billion included approximately $32.4 billion of cash and cash equivalents (of which $5.2 billion was available for general corporate use), $46.3 billion of debt securities and $4.9 billion of investments in equity securities. Given the significant portion of our portfolio held in cash and cash equivalents, we do not anticipate fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position. Our available-for-sale debt securities portfolio had a weighted-average duration of 4.0 years and a weighted-average credit rating of “Double A” as of September 30, 2024. When multiple credit ratings are available for an individual security, the average of the available ratings is used to determine the weighted-average credit rating.

23
Capital Resources and Uses of Liquidity
In addition to cash flows from operations and cash and cash equivalent balances available for general corporate use, our capital resources and uses of liquidity are as follows:
Cash Requirements. A summary of our cash requirements as of December 31, 2023 was disclosed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2023 10-K. During the nine months ended September 30, 2024, there were no material changes to this previously disclosed information outside the ordinary course of business. We believe our capital resources are sufficient to meet future, short-term and long-term, liquidity needs. We continually evaluate opportunities to expand our operations, including through internal development of new products, programs and technology applications and business combinations.
Short-Term Borrowings. Our revolving bank credit facilities provide liquidity support for our commercial paper borrowing program, which facilitates the private placement of unsecured debt through independent broker-dealers, and are available for general corporate purposes. For more information on our commercial paper and bank credit facilities, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2023 10-K.
Our revolving bank credit facilities contain various covenants, including covenants requiring us to maintain a defined debt to debt-plus-shareholders’ equity ratio of not more than 60%. As of September 30, 2024, our debt to debt-plus-shareholders’ equity ratio, as defined and calculated under the credit facilities, was approximately 43%.
Long-Term Debt. Periodically, we access capital markets and issue long-term debt for general corporate purposes, such as to meet our working capital requirements, to refinance debt, to finance acquisitions or for share repurchases. For more information on our long-term debt, see Note 5 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report and Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2023 10-K.
Credit Ratings. Our credit ratings as of September 30, 2024 were as follows:
  
Moody’sS&P GlobalFitchA.M. Best
 RatingsOutlookRatingsOutlookRatingsOutlookRatingsOutlook
Senior unsecured debtA2StableA+StableAStableAStable
Commercial paperP-1n/aA-1n/aF1n/aAMB-1+n/a
The availability of financing in the form of debt or equity is influenced by many factors, including our profitability, operating cash flows, debt levels, credit ratings, debt covenants and other contractual restrictions, regulatory requirements and economic and market conditions. A significant downgrade in our credit ratings or adverse conditions in the capital markets may increase the cost of borrowing for us or limit our access to capital.
Share Repurchase Program. During the nine months ended September 30, 2024, we repurchased approximately 7.7 million shares at an average price of $521.21 per share. In June 2024, our Board of Directors amended our share repurchase program to authorize the repurchase of up to 35 million shares of Common Stock, in addition to all remaining shares authorized to be repurchased under the Board’s 2018 renewal of the program. As of September 30, 2024, we had Board of Directors’ authorization to purchase up to 42 million shares of our common stock. The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the program.
Dividends. In June 2024, our Board of Directors increased our quarterly cash dividend to an annual rate of $8.40 compared to $7.52 per share, which we had paid since June 2023. For more information on our dividend, see Note 7 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
Pending Transactions. As of September 30, 2024, the Company had entered into transaction agreements in the health care sector, subject to regulatory approval and/or other customary closing conditions. The total anticipated consideration required for these transactions, excluding the payoff of acquired indebtedness, was approximately $5 billion.
For additional liquidity discussion, see Note 10 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II, Item 7 in our 2023 10-K.

24
RECENTLY ISSUED ACCOUNTING STANDARDS
There are no recently issued accounting standards that are expected to have a material impact on our Condensed Consolidated Financial Statements.
CRITICAL ACCOUNTING ESTIMATES
In preparing our Condensed Consolidated Financial Statements, we are required to make judgments, assumptions and estimates, which we believe are reasonable and prudent based on the available facts and circumstances. These judgments, assumptions and estimates affect certain of our revenues and expenses and their related balance sheet accounts and disclosure of our contingent liabilities. We base our assumptions and estimates primarily on historical experience and consider known and projected trends. On an ongoing basis, we re-evaluate our selection of assumptions and the method of calculating our estimates. Actual results, however, may materially differ from our calculated estimates, and this difference would be reported in our current operations.
Our critical accounting estimates include medical costs payable and goodwill. For a detailed description of our critical accounting estimates, see “Management’s Discussion and Analysis of Financial Condition and Results of Operations” included in Part II, Item 7 in our 2023 10-K. For a detailed discussion of our significant accounting policies, see Note 2 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in our 2023 10-K.
FORWARD-LOOKING STATEMENTS
The statements, estimates, projections, guidance or outlook contained in this document include “forward-looking” statements which are intended to take advantage of the “safe harbor” provisions of the federal securities laws. The words “believe,” “expect,” “intend,” “estimate,” “anticipate,” “forecast,” “outlook,” “plan,” “project,” “should” and similar expressions identify forward-looking statements. These statements may contain information about financial prospects, economic conditions and trends and involve risks and uncertainties. Actual results could differ materially from those that management expects, depending on the outcome of certain factors including: our ability to effectively estimate, price for and manage medical costs; new or changes in existing health care laws or regulations, or their enforcement or application; cyberattacks, other privacy/data security incidents, or our failure to comply with related regulations; reductions in revenue or delays to cash flows received under government programs; changes in Medicare, the CMS star ratings program or the application of risk adjustment data validation audits; the DOJ’s legal action relating to the risk adjustment submission matter; our ability to maintain and achieve improvement in quality scores impacting revenue; failure to maintain effective and efficient information systems or if our technology products do not operate as intended; risks and uncertainties associated with our businesses providing pharmacy care services; competitive pressures, including our ability to maintain or increase our market share; changes in or challenges to our public sector contract awards; failure to achieve targeted operating cost productivity improvements; failure to develop and maintain satisfactory relationships with health care payers, physicians, hospitals and other service providers; the impact of potential changes in tax laws and regulations; increases in costs and other liabilities associated with litigation, government investigations, audits or reviews; failure to complete, manage or integrate strategic transactions; risk and uncertainties associated with the continuing sale of operations in South America; risks associated with public health crises arising from large-scale medical emergencies, pandemics, natural disasters and other extreme events; failure to attract, develop, retain, and manage the succession of key employees and executives; our investment portfolio performance; impairment of our goodwill and intangible assets; failure to protect proprietary rights to our databases, software and related products; downgrades in our credit ratings; and our ability to obtain sufficient funds from our regulated subsidiaries or from external financings to fund our obligations, reinvest in our business, maintain our debt to total capital ratio at targeted levels, maintain our quarterly dividend payment cycle, or continue repurchasing shares of our common stock.
This above list is not exhaustive. We discuss these matters, and certain risks that may affect our business operations, financial condition and results of operations, more fully in our filings with the SEC, including our reports on Forms 10-K, 10-Q and 8-K. By their nature, forward-looking statements are not guarantees of future performance or results and are subject to risks, uncertainties and assumptions that are difficult to predict or quantify. Actual results may vary materially from expectations expressed or implied in this document or any of our prior communications. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made. We do not undertake to update or revise any forward-looking statements, except as required by law.
25
ITEM 3.    QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We manage exposure to market interest rates by diversifying investments across different fixed-income market sectors and debt across maturities, as well as by matching a portion of our floating-rate assets and liabilities, either directly or through the use of interest rate swap contracts. Unrealized gains and losses on investments in available-for-sale debt securities are reported in comprehensive income.
The following table summarizes the impact of hypothetical changes in market interest rates across the entire yield curve by 1% point or 2% points as of September 30, 2024 on our investment income and interest expense per annum, and the fair value of our investments and debt (in millions, except percentages):
September 30, 2024
Increase (Decrease) in Market Interest RateInvestment
Income Per
Annum		Interest
Expense Per
Annum		Fair Value of
Financial Assets		Fair Value of
Financial Liabilities
2 %$824 $457 $(3,773)$(10,539)
1412 229 (1,936)(5,745)
(1)(412)(212)2,015 7,016 
(2)(824)(423)4,083 15,514 
Note: The impact of hypothetical changes in interest rates may not reflect the full 100 or 200 basis point change on interest income and interest expense or on the fair value of financial assets and liabilities as the rates are assumed to not fall below zero.
ITEM 4.    CONTROLS AND PROCEDURES
EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES
We maintain disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (Exchange Act) that are designed to provide reasonable assurance that information required to be disclosed by us in reports that we file or submit under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in SEC rules and forms; and (ii) accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.
In connection with the filing of this quarterly report on Form 10-Q, management evaluated, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, the effectiveness of the design and operation of our disclosure controls and procedures as of September 30, 2024. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2024.
CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING
There have been no changes in our internal control over financial reporting during the quarter ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
ITEM 1.    LEGAL PROCEEDINGS
A description of our legal proceedings is included in and incorporated by reference to Note 8 of Notes to the Condensed Consolidated Financial Statements included in Part I, Item 1 of this report.
ITEM 1A.    RISK FACTORS
In addition to the other information set forth in this report, you should carefully consider the factors discussed in Part I, Item 1A, “Risk Factors” of our 2023 10-K, which could materially affect our business, financial condition or future results. The risks described in our 2023 10-K are not the only risks facing us. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition or future results.
There have been no material changes to the risk factors as disclosed in our 2023 10-K.
26
ITEM 2.    UNREGISTERED SALE OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities (a)
Third Quarter 2024
For the Month EndedTotal Number of Shares PurchasedAverage Price Paid Per ShareTotal Number of Shares Purchased as Part of Publicly Announced Plans or ProgramsMaximum Number of Shares That May Yet Be Purchased Under The Plans or Programs
(in millions)(in millions)(in millions)
July 30, 20240.1 $571.53 0.1 43.7
August 31, 20241.3 577.00 1.3 42.4
September 30, 20240.2 596.03 0.2 42.2
Total1.6 1.6 
(a)    In November 1997, our Board of Directors adopted a share repurchase program, which the Board of Directors evaluates periodically. In June 2024, the Board of Directors amended our share repurchase program to authorize the repurchase of up to 35 million shares of our common stock in open market purchases or other types of transactions (including prepaid or structured repurchase programs), in addition to all remaining shares authorized to be repurchased under the Board’s 2018 renewal of the program. There is no established expiration date for the program. The Board of Directors from time to time may further amend the share repurchase program in order to increase the authorized number of shares which may be repurchased under the program.
ITEM 5.    OTHER INFORMATION
Trading Arrangements
During the quarter ended September 30, 2024, none of the Company’s directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated any contract, instruction or written plan for the purchase or sale of Company securities intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or any non-Rule 10b5-1 trading arrangement.
27

ITEM 6.    EXHIBITS*
The following exhibits are filed or incorporated by reference herein in response to Item 601 of Regulation S-K. The Company files Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K pursuant to the Securities Exchange Act of 1934 under Commission File No. 1-10864.
101.INSXBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHInline XBRL Taxonomy Extension Schema Document.
101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.
101.LABInline XBRL Taxonomy Extension Label Linkbase Document.
101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.
104 Cover Page Interactive Data File (formatted as Inline XBRL and embedded within Exhibit 101).
 ________________
*Pursuant to Item 601(b)(4)(iii) of Regulation S-K, copies of instruments defining the rights of certain holders of long-term debt are not filed. The Company will furnish copies thereof to the SEC upon request.
28
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
UNITEDHEALTH GROUP INCORPORATED
 
/s/ ANDREW WITTY
Chief Executive Officer
(principal executive officer)		Dated:November 4, 2024
Andrew Witty  
/s/ JOHN REX
President and Chief Financial Officer
(principal financial officer)		Dated:November 4, 2024
John Rex  
/s/ THOMAS ROOS
Senior Vice President and
Chief Accounting Officer
(principal accounting officer)		Dated:November 4, 2024
Thomas Roos  
29

EXHIBIT 31.1
CERTIFICATIONS PURSUANT TO SECTION 302 OF THE
SARBANES-OXLEY ACT OF 2002
Certification of Principal Executive Officer

 I, Andrew P. Witty, certify that:

1.I have reviewed this report on Form 10-Q of UnitedHealth Group Incorporated (the “registrant”);
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

 
November 4, 2024
/s/ ANDREW P. WITTY
 Andrew P. Witty
Chief Executive Officer



Certification of Principal Financial Officer

I, John F. Rex, certify that:

1.I have reviewed this report on Form 10-Q of UnitedHealth Group Incorporated (the “registrant”);
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.


 
November 4, 2024
/s/ JOHN F. REX
 John F. Rex
President and Chief Financial Officer



EXHIBIT 32.1
CERTIFICATIONS PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Certification of Principal Executive Officer
In connection with the report of UnitedHealth Group Incorporated (the “Company”) on Form 10-Q for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Andrew P. Witty, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
November 4, 2024
/s/ ANDREW P. WITTY
 Andrew P. Witty
Chief Executive Officer
Certification of Principal Financial Officer
In connection with the report of UnitedHealth Group Incorporated (the “Company”) on Form 10-Q for the period ended September 30, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, John F. Rex, certify pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


 
November 4, 2024
/s/ JOHN F. REX
 John F. Rex
President and Chief Financial Officer

v3.24.3
Document and Entity Information Document - shares
 9 Months Ended
Sep. 30, 2024
Oct. 31, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2024  
Document Transition Report false  
Entity File Number 1-10864  
Entitiy Registrant Name UnitedHealth Group Incorporated  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 41-1321939  
Entity Address, Address Line One 9900 Bren Road East  
Entity Address, City or Town Minnetonka,  
Entity Address, State or Province MN  
Entity Address, Postal Zip Code 55343  
Other Address, Address line one 655 New York Avenue NW  
Other Entity Address, City or Town Washington,  
Other Entity Address, State or Province DC  
Other Entity Address, Postal Zip Code 20001  
City Area Code (800)  
Local Phone Number 328-5979  
Title of 12(b) Security Common Stock, $.01 par value  
Trading Symbol UNH  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entitiy Central Index Key 0000731766  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q3  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   920,284,334
v3.24.3
Condensed Consolidated Balance Sheets - USD ($)
shares in Millions, $ in Millions
Sep. 30, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 32,400 $ 25,427
Short-term investments 4,734 4,201
Accounts receivable, net 20,024 21,276
Other current receivables, net 27,461 17,694
Assets under management 0 3,755
Prepaid expenses and other current assets 7,639 6,084
Total current assets 92,258 78,437
Long-term investments 48,689 47,609
Property, equipment and capitalized software, net 10,139 11,450
Goodwill 105,978 103,732
Other intangible assets, net 23,594 15,194
Other assets 18,651 17,298
Total assets 299,309 273,720
Current liabilities:    
Medical costs payable 33,951 32,395
Accounts payable and accrued liabilities 33,080 31,958
Short-term borrowings and current maturities of long-term debt 3,909 4,274
Unearned revenues 3,320 3,355
Other current liabilities 27,305 27,072
Total current liabilities 101,565 99,054
Long-term debt, less current maturities 74,101 58,263
Deferred income taxes 4,014 3,021
Other liabilities 15,174 14,463
Total liabilities 194,854 174,801
Commitments and contingencies (Note 8)
Redeemable noncontrolling interests 4,574 4,498
Equity:    
Preferred stock, $0.001 par value - 10 shares authorized; no shares issued or outstanding 0 0
Common stock, $0.01 par value - 3,000 shares authorized; 923 and 924 issued and outstanding 9 9
Additional paid-in capital 461 0
Retained earnings 96,518 95,774
Accumulated other comprehensive loss (2,453) (7,027)
Nonredeemable noncontrolling interests 5,346 5,665
Total equity 99,881 94,421
Total liabilities, redeemable noncontrolling interests and equity $ 299,309 $ 273,720
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 10 10
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.01 $ 0.01
Common stock, shares authorized 3,000 3,000
Common stock, shares issued 923 924
Common stock, shares outstanding 923 924
v3.24.3
Condensed Consolidated Statements of Operations - USD ($)
shares in Millions, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Revenues:        
Premiums $ 77,442 $ 72,339 $ 232,327 $ 217,599
Investment and other income 1,643 997 3,651 2,910
Total revenues 100,820 92,361 299,471 277,195
Operating costs:        
Medical Costs 65,957 59,550 197,150 179,663
Operating costs 13,280 13,855 40,519 41,289
Cost of products sold 11,834 9,423 34,230 28,576
Depreciation and amortization 1,041 1,007 3,058 2,998
Total operating costs 92,112 83,835 274,957 252,526
Earnings from operations 8,708 8,526 24,514 24,669
Interest expense (1,074) (834) (2,903) (2,416)
Loss on sale of subsidiary and subsidiaries held for sale (20) 0 (8,331) 0
Earnings before income taxes 7,614 7,692 13,280 22,253
Provision for income taxes (1,356) (1,654) (3,822) (4,784)
Net earnings 6,258 6,038 9,458 17,469
Earnings attributable to noncontrolling interests (203) (197) (596) (543)
Net earnings attributable to UnitedHealth Group common shareholders $ 6,055 $ 5,841 $ 8,862 $ 16,926
Earnings per share attributable to UnitedHealth Group common shareholders:        
Basic $ 6.56 $ 6.31 $ 9.61 $ 18.20
Diluted $ 6.51 $ 6.24 $ 9.53 $ 18.01
Basic weighted-average number of common shares outstanding 923 926 922 930
Dilutive effect of common share equivalents 7 10 8 10
Diluted weighted-average number of common shares outstanding 930 936 930 940
Anti-dilutive shares excluded from the calculation of dilutive effect of common share equivalents 4 6 6 6
Products        
Revenues:        
Revenue from Products and Services $ 12,631 $ 10,354 $ 36,751 $ 31,272
Services        
Revenues:        
Revenue from Products and Services $ 9,104 $ 8,671 $ 26,742 $ 25,414
v3.24.3
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Net earnings $ 6,258 $ 6,038 $ 9,458 $ 17,469
Other comprehensive income (loss):        
Gross unrealized gains (losses) on investment securities during the period 1,434 (893) 1,069 (684)
Income tax effect (328) 204 (243) 156
Total unrealized gains (losses), net of tax 1,106 (689) 826 (528)
Gross reclassification adjustment for net realized (gains) losses included in net earnings (291) 7 (349) (27)
Income tax effect 67 (2) 80 6
Total reclassification adjustment, net of tax (224) 5 (269) (21)
Foreign currency translation gains (losses) 88 (354) (197) 254
Reclassification adjustment for translation losses included in net earnings 0 0 4,214 0
Total foreign currency translation gains (losses) 88 (354) 4,017 254
Other comprehensive income (loss) 970 (1,038) 4,574 (295)
Comprehensive income 7,228 5,000 14,032 17,174
Comprehensive income attributable to noncontrolling interests (203) (197) (596) (543)
Comprehensive income attributable to UnitedHealth Group common shareholders $ 7,025 $ 4,803 $ 13,436 $ 16,631
v3.24.3
Condensed Consolidated Statements of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Common Stock [Member]
Additional Paid-In Capital [Member]
Retained Earnings [Member]
Net Unrealized (Losses) Gains on Investments [Member]
Foreign Currency Translation (Losses) Gains [Member]
Nonredeemable Noncontrolling Interests [Member]
Balance at Dec. 31, 2022 $ 81,450 $ 9 $ 0 $ 86,156 $ (2,778) $ (5,615) $ 3,678
Balance (in shares) at Dec. 31, 2022   934          
Net earnings attributable to UnitedHealth Group common shareholders 16,926     16,926      
Net earnings attributable to nonredeemable noncontrolling interest             401
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest 17,327            
Other comprehensive income (loss) (295)       (549) 254  
Issuances of common stock, and related tax effects (in shares)   4          
Issuances of common stock, and related tax effects 963 $ 0 963        
Share-based compensation 833   833        
Common share repurchases (in shares)   (13)          
Common share repurchases (6,549) $ 0 (1,663) (4,886)      
Cash dividends paid on common shares (5,023)     (5,023)      
Redeemable noncontrolling interests fair value and other adjustments (133)   (133)        
Acquisition and other adjustments of nonredeemable noncontrolling interests 1,339           1,339
Distribution to nonredeemable noncontrolling interests (348)           (348)
Balance at Sep. 30, 2023 $ 89,564 $ 9 0 93,173 (3,327) (5,361) 5,070
Balance (in shares) at Sep. 30, 2023   925          
Common Stock, Dividends, Per Share, Cash Paid $ 5.41            
Balance at Jun. 30, 2023 $ 87,368 $ 9 0 89,994 (2,643) (5,007) 5,015
Balance (in shares) at Jun. 30, 2023   927          
Net earnings attributable to UnitedHealth Group common shareholders 5,841     5,841      
Net earnings attributable to nonredeemable noncontrolling interest             149
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest 5,990            
Other comprehensive income (loss) (1,038)       (684) (354)  
Issuances of common stock, and related tax effects (in shares)   1          
Issuances of common stock, and related tax effects 395 $ 0 395        
Share-based compensation 235   235        
Common share repurchases (in shares)   (3)          
Common share repurchases (1,511) $ 0 (588) (923)      
Cash dividends paid on common shares (1,739)     (1,739)      
Redeemable noncontrolling interests fair value and other adjustments (42)   (42)        
Acquisition and other adjustments of nonredeemable noncontrolling interests 42           42
Distribution to nonredeemable noncontrolling interests (136)           (136)
Balance at Sep. 30, 2023 $ 89,564 $ 9 0 93,173 (3,327) (5,361) 5,070
Balance (in shares) at Sep. 30, 2023   925          
Common Stock, Dividends, Per Share, Cash Paid $ 1.88            
Balance at Dec. 31, 2023 $ 94,421 $ 9 0 95,774 (1,971) (5,056) 5,665
Balance (in shares) at Dec. 31, 2023 924 924          
Net earnings attributable to UnitedHealth Group common shareholders $ 8,862     8,862      
Net earnings attributable to nonredeemable noncontrolling interest             462
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest 9,324            
Other comprehensive income (loss) 4,574       557 4,017  
Issuances of common stock, and related tax effects (in shares)   7          
Issuances of common stock, and related tax effects 1,280 $ 0 1,280        
Share-based compensation 770   770        
Common share repurchases (in shares)   (8)          
Common share repurchases (4,045) $ 0 (1,528) (2,517)      
Cash dividends paid on common shares (5,601)     (5,601)      
Redeemable noncontrolling interests fair value and other adjustments (61)   (61)        
Acquisition and other adjustments of nonredeemable noncontrolling interests (291)           (291)
Distribution to nonredeemable noncontrolling interests (490)           (490)
Balance at Sep. 30, 2024 $ 99,881 $ 9 461 96,518 (1,414) (1,039) 5,346
Balance (in shares) at Sep. 30, 2024 923 923          
Common Stock, Dividends, Per Share, Cash Paid $ 6.08            
Balance at Jun. 30, 2024 $ 94,676 $ 9 373 92,400 (2,296) (1,127) 5,317
Balance (in shares) at Jun. 30, 2024   921          
Net earnings attributable to UnitedHealth Group common shareholders 6,055     6,055      
Net earnings attributable to nonredeemable noncontrolling interest             155
Net Earnings, Including Portion Attributable to Nonredeemable Noncontrolling Interest 6,210            
Other comprehensive income (loss) 970       882 88  
Issuances of common stock, and related tax effects (in shares)   4          
Issuances of common stock, and related tax effects 842 $ 0 842        
Share-based compensation 208   208        
Common share repurchases (in shares)   (2)          
Common share repurchases (957) $ 0 (957) 0      
Cash dividends paid on common shares (1,937)     (1,937)      
Redeemable noncontrolling interests fair value and other adjustments (5)   (5)        
Acquisition and other adjustments of nonredeemable noncontrolling interests 28           28
Distribution to nonredeemable noncontrolling interests (154)           (154)
Balance at Sep. 30, 2024 $ 99,881 $ 9 $ 461 $ 96,518 $ (1,414) $ (1,039) $ 5,346
Balance (in shares) at Sep. 30, 2024 923 923          
Common Stock, Dividends, Per Share, Cash Paid $ 2.10            
v3.24.3
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Operating activities    
Net earnings $ 9,458 $ 17,469
Noncash items:    
Depreciation and amortization 3,058 2,998
Deferred income taxes (234) (494)
Share-based compensation 831 851
Loss on sale of subsidiary and subsidiaries held for sale 8,331 0
Other, net (610) (59)
Net change in other operating items, net of effects from acquisitions and dispositions:    
Accounts receivable 685 (2,574)
Other assets (2,988) (2,358)
Medical costs payable 2,235 3,837
Accounts payable and other liabilities 1,250 2,370
Unearned revenues (181) 12,221
Cash flows from operating activities 21,835 34,261
Investing activities    
Purchases of investments (19,951) (12,998)
Sales of investments 15,065 3,674
Maturities of investments 6,738 6,474
Cash paid for acquisitions and other transactions, net of cash assumed (11,674) (8,389)
Purchases of property, equipment and capitalized software (2,587) (2,427)
Loans to care providers - cyberattack (8,904) 0
Repayments of care provider loans - cyberattack 3,189 0
Other, net (1,284) (721)
Cash flows used for investing activities (19,408) (14,387)
Financing activities    
Common share repurchases (4,028) (6,500)
Cash dividends paid (5,601) (5,023)
Proceeds from common stock issuances 1,611 1,039
Repayments of long-term debt (2,500) (2,125)
(Repayments of) proceeds from short-term borrowings, net (191) 1,579
Proceeds from issuance of long-term debt 17,811 6,394
Customer funds administered (1,059) 2,037
Other, net (1,213) (1,774)
Cash flows from (used for) financing activities 4,830 (4,373)
Effect of exchange rate changes on cash and cash equivalents (30) 49
Increase in cash and cash equivalents, including cash within businesses held for sale 7,227 15,550
Less: cash within businesses held for sale (254) 0
Net increase in cash and cash equivalents 6,973 15,550
Cash and cash equivalents, beginning of period 25,427 23,365
Cash and cash equivalents, end of period $ 32,400 $ 38,915
v3.24.3
Basis of Presentation (Notes)
 9 Months Ended
Sep. 30, 2024
Basis of Presentation and Significant Accounting Policies [Text Block] Basis of Presentation
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. The Company’s two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.
The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC (2023 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.
Use of Estimates
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
Revenues - Products and Services
As of September 30, 2024 and December 31, 2023, accounts receivable related to products and services were $9.2 billion and $8.6 billion, respectively. As of September 30, 2024, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $13.0 billion, of which approximately half is expected to be recognized in the next three years.
Assets Under Management
In July 2024, the Company amended and restated its Medicare Supplement Program with a membership organization (the Medicare Supplement Program). The amendments provide the Company the right to use a trade name and other intellectual property in marketing efforts for Medicare Supplement offerings. Amounts previously reported as assets under management are now included within the Company’s Condensed Consolidated Balance Sheet based upon their classification.
For periods prior to the amended and restated Medicare Supplement Program, the Company excluded the effects of certain balance sheet amounts in its Condensed Consolidated Statements of Cash Flows, while these effects are included for periods after the amendments.
v3.24.3
Investments (Notes)
 9 Months Ended
Sep. 30, 2024
Investments [Abstract]  
Investments [Text Block] Investments
A summary of debt securities by major security type is as follows:
(in millions)Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
September 30, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations$5,005 $5 $(182)$4,828 
State and municipal obligations7,301 23 (256)7,068 
Corporate obligations23,752 82 (781)23,053 
U.S. agency mortgage-backed securities9,209 21 (600)8,630 
Non-U.S. agency mortgage-backed securities2,832 6 (154)2,684 
Total debt securities - available-for-sale48,099 137 (1,973)46,263 
Debt securities - held-to-maturity:
U.S. government and agency obligations414 1 (2)413 
State and municipal obligations28 — (2)26 
Corporate obligations22 — — 22 
Total debt securities - held-to-maturity464 1 (4)461 
Total debt securities$48,563 $138 $(1,977)$46,724 
December 31, 2023
Debt securities - available-for-sale:
U.S. government and agency obligations$4,674 $3 $(234)$4,443 
State and municipal obligations7,636 39 (322)7,353 
Corporate obligations23,136 67 (1,186)22,017 
U.S. agency mortgage-backed securities8,982 22 (708)8,296 
Non-U.S. agency mortgage-backed securities3,023 3 (240)2,786 
Total debt securities - available-for-sale47,451 134 (2,690)44,895 
Debt securities - held-to-maturity:
U.S. government and agency obligations506 1 (6)501 
State and municipal obligations28 — (2)26 
Corporate obligations69 — — 69 
Total debt securities - held-to-maturity603 1 (8)596 
Total debt securities$48,054 $135 $(2,698)$45,491 
The Company held $4.9 billion of equity securities as of September 30, 2024 and December 31, 2023. The Company’s investments in equity securities primarily consist of venture investments and employee savings plan related investments. Additionally, the Company’s investments included $1.8 billion and $1.4 billion of equity method investments primarily in operating businesses in the health care sector as of September 30, 2024 and December 31, 2023, respectively. The allowance for credit losses on held-to-maturity securities at September 30, 2024 and December 31, 2023 was not material.
The amortized cost and fair value of debt securities as of September 30, 2024, by contractual maturity, were as follows:
Available-for-SaleHeld-to-Maturity
(in millions)Amortized
Cost		Fair
Value		Amortized
Cost		Fair
Value
Due in one year or less$4,881 $4,861 $320 $319 
Due after one year through five years15,152 14,810 113 114 
Due after five years through ten years10,993 10,432 14 13 
Due after ten years5,032 4,846 17 15 
U.S. agency mortgage-backed securities9,209 8,630 — — 
Non-U.S. agency mortgage-backed securities2,832 2,684 — — 
Total debt securities$48,099 $46,263 $464 $461 
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:
 Less Than 12 Months12 Months or Greater Total
(in millions)Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses
September 30, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations
$894 $(7)$2,448 $(175)$3,342 $(182)
State and municipal obligations726 (6)4,278 (250)5,004 (256)
Corporate obligations3,499 (18)12,174 (763)15,673 (781)
U.S. agency mortgage-backed securities2,140 (20)5,018 (580)7,158 (600)
Non-U.S. agency mortgage-backed securities
138 (1)1,990 (153)2,128 (154)
Total debt securities - available-for-sale$7,397 $(52)$25,908 $(1,921)$33,305 $(1,973)
December 31, 2023
Debt securities - available-for-sale:
U.S. government and agency obligations
$1,270 $(7)$2,077 $(227)$3,347 $(234)
State and municipal obligations907 (7)4,063 (315)4,970 (322)
Corporate obligations1,826 (17)14,696 (1,169)16,522 (1,186)
U.S. agency mortgage-backed securities1,337 (12)5,069 (696)6,406 (708)
Non-U.S. agency mortgage-backed securities
279 (6)2,202 (234)2,481 (240)
Total debt securities - available-for-sale$5,619 $(49)$28,107 $(2,641)$33,726 $(2,690)
The Company’s unrealized losses from debt securities as of September 30, 2024 were generated from approximately 27,000 positions out of a total of 41,000 positions. The Company believes that it will timely collect the principal and interest due on its debt securities that have an amortized cost in excess of fair value. The unrealized losses were primarily caused by interest rate increases and not by unfavorable changes in the credit quality associated with these securities which impacted the Company’s assessment on collectability of principal and interest. At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of September 30, 2024, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary. The allowance for credit losses on available-for-sale debt securities at September 30, 2024 and December 31, 2023 was not material.
v3.24.3
Fair Value (Notes)
 9 Months Ended
Sep. 30, 2024
Fair Value Disclosures [Abstract]  
Fair Value [Text Block] Fair Value
Certain assets and liabilities are measured at fair value in the Condensed Consolidated Financial Statements or have fair values disclosed in the Notes to the Condensed Consolidated Financial Statements. These assets and liabilities are classified into one of three levels of a hierarchy defined by GAAP.
For a description of the methods and assumptions that are used to estimate the fair value and determine the fair value hierarchy classification of each class of financial instrument, see Note 4 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2023 10-K.
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)		Total
Fair and Carrying
Value
September 30, 2024
Cash and cash equivalents$32,230$170$—$32,400
Debt securities - available-for-sale:
U.S. government and agency obligations4,682146—4,828
State and municipal obligations—7,068—7,068
Corporate obligations2722,71930723,053
U.S. agency mortgage-backed securities—8,630—8,630
Non-U.S. agency mortgage-backed securities—2,684—2,684
Total debt securities - available-for-sale4,70941,24730746,263
Equity securities1,83325651,923
Total assets at fair value$38,772$41,442$372$80,586
Percentage of total assets at fair value48 %51 %1 %100 %
December 31, 2023
Cash and cash equivalents$25,345$82$—$25,427
Debt securities - available-for-sale:
U.S. government and agency obligations4,167276—4,443
State and municipal obligations—7,353—7,353
Corporate obligations1521,80020222,017
U.S. agency mortgage-backed securities—8,296—8,296
Non-U.S. agency mortgage-backed securities—2,786—2,786
Total debt securities - available-for-sale4,18240,51120244,895
Equity securities2,46816692,553
Assets under management 1,5052,1401103,755
Total assets at fair value$33,500$42,749$381$76,630
Percentage of total assets at fair value44 %55 %1 %100 %
There were no transfers in or out of Level 3 financial assets or liabilities during the nine months ended September 30, 2024 or 2023.
The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)		Total
Fair
Value		Total Carrying Value
September 30, 2024
Debt securities - held-to-maturity$435 $26 $— $461 $464 
Long-term debt and other financing obligations$— $75,798 $— $75,798 $76,780 
December 31, 2023
Debt securities - held-to-maturity$524 $72 $— $596 $603 
Long-term debt and other financing obligations$— $59,851 $— $59,851 $61,449 
Nonfinancial assets and liabilities or financial assets and liabilities that are measured at fair value on a nonrecurring basis are subject to fair value adjustments only in certain circumstances, such as when the Company records an impairment. The assets and liabilities within our South American operations held for sale as of September 30, 2024 were measured at the lower of carrying value or fair value less cost to sell. Fair value is measured based upon unobservable amounts, such as estimated selling price derived from Company-specific information and market conditions. There were no other significant fair value adjustments for assets and liabilities recorded during the nine months ended September 30, 2024 or 2023.
v3.24.3
Medical Costs Payable (Notes)
 9 Months Ended
Sep. 30, 2024
Insurance [Abstract]  
Short-Duration Insurance and Deposit Contracts Medical Costs Payable
The following table shows the components of the change in medical costs payable for the nine months ended September 30:
(in millions)20242023
Medical costs payable, beginning of period$32,395 $29,056 
Acquisitions (dispositions), net(755)1 
Reported medical costs:
Current year197,750 180,423 
Prior years(600)(760)
Total reported medical costs197,150 179,663 
Medical payments:
Payments for current year
(165,544)(149,671)
Payments for prior years(29,095)(26,257)
Total medical payments(194,639)(175,928)
Less: medical costs payable included within businesses held for sale(200)— 
Medical costs payable, end of period$33,951 $32,792 
For the nine months ended September 30, 2024 and 2023, prior years’ medical cost reserve development included no individual factors that were significant. Medical costs payable included reserves for claims incurred by consumers but not yet reported to the Company of $24.1 billion and $22.3 billion at September 30, 2024 and December 31, 2023, respectively.
v3.24.3
Short-Term Borrowings and Long-Term Debt (Notes)
 9 Months Ended
Sep. 30, 2024
Debt Disclosure [Abstract]  
Debt Disclosure Short-Term Borrowings and Long-Term Debt
In March 2024, the Company issued $6.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages)Par Value
4.600% notes due April 2027
$500 
4.700% notes due April 2029
400 
4.900% notes due April 2031
1,000 
5.000% notes due April 2034
1,250 
5.375% Notes due April 2054
1,750 
5.500% Notes due April 2064
1,100 
In July 2024, the Company issued $12.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages)Par Value
Floating rate notes due July 2026
$500 
4.750% notes due July 2026
650 
4.800% notes due January 2030
1,250 
4.950% notes due January 2032
1,500 
5.150% notes due July 2034
2,000 
5.500% notes due July 2044
1,500 
5.625% notes due July 2054
2,750 
5.750% notes due July 2064
1,850 
As of September 30, 2024, the Company had $1.2 billion of commercial paper outstanding, with a weighted-average annual interest rate of 5.4%.
In May 2024, the Company entered into an additional $3 billion 364-day revolving bank credit facility and a $5 billion 364-day delayed draw term loan. The $5 billion 364-day delayed draw term loan was terminated in September 2024. As of September 30, 2024 no amount had been drawn on any of the bank credit facilities.
For more information on the Company’s short-term borrowings, debt covenants and long-term debt, see Note 8 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2023 10-K.
v3.24.3
Other Intangible Assets (Notes)
 9 Months Ended
Sep. 30, 2024
Other Intangible Assets [Abstract]  
Other Intangible Assets Disclosure Other Intangible Assets
The fair values and weighted-average useful lives assigned to intangible assets as a result of transactions completed during the nine months ended September 30, 2024 consisted of the following:
(in millions, except years)Fair ValueWeighted-Average Useful Life
Customer-related$1,070 13 years
Trademarks and technology509 5 years
Other20 8 years
Total finite-lived$1,599 11 years
Total indefinite-lived - trade names, trademarks, operating licenses and certificates and other8,793 
Total intangible assets$10,392 
v3.24.3
Shareholders' Equity (Notes)
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Stockholders' Equity Note Disclosure Shareholders’ Equity
Share Repurchase Program
In June 2024, the Company’s Board of Directors amended the Company’s share repurchase program to authorize the repurchase of up to 35 million shares of Common Stock, in addition to all remaining shares authorized to be repurchased under the Board’s 2018 renewal of the program. As of September 30, 2024, the Company had 42 million shares remaining available under its share repurchase authorization.
Dividends
In June 2024, the Company’s Board of Directors increased the Company’s quarterly cash dividend to shareholders to an annual rate of $8.40 compared to $7.52 per share, which the Company had paid since June 2023. Declaration and payment of future quarterly dividends is at the discretion of the Board of Directors and may be adjusted as business needs or market conditions change.
The following table provides details of the Company’s dividend payments during the nine months ended September 30, 2024:
Payment DateAmount per ShareTotal Amount Paid
(in millions)
March 19$1.88 $1,729 
June 252.10 1,935 
September 242.10 1,937 
v3.24.3
Commitments and Contingencies (Notes)
 9 Months Ended
Sep. 30, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies
Pending Transactions
As of September 30, 2024, the Company had entered into transaction agreements in the health care sector, subject to regulatory approval and/or other customary closing conditions. The total anticipated consideration required for these transactions, excluding the payoff of acquired indebtedness, was approximately $5 billion.
Legal Matters
The Company is frequently made party to a variety of legal actions and regulatory inquiries, including class actions and suits brought by members, care providers, consumer advocacy organizations, customers and regulators, relating to the Company’s businesses, including management and administration of health benefit plans and other services. These matters include medical malpractice, employment, intellectual property, antitrust, privacy and contract claims and claims related to health care benefits coverage and other business practices.
The Company records liabilities for its estimates of probable costs resulting from these matters where appropriate. Estimates of costs resulting from legal and regulatory matters involving the Company are inherently difficult to predict, particularly where the matters: involve indeterminate claims for monetary damages or may involve fines, penalties or punitive damages; present novel legal theories or represent a shift in regulatory policy; involve a large number of claimants or regulatory bodies; are in the early stages of the proceedings; or could result in a change in business practices. Accordingly, the Company is often unable to estimate the losses or ranges of losses for those matters where there is a reasonable possibility or it is probable a loss may be incurred.
Government Investigations, Audits and Reviews
The Company has been involved or is currently involved in various governmental investigations, audits and reviews. These include routine, regular and special investigations, audits and reviews by the Centers for Medicare and Medicaid Services (CMS), state insurance and health and welfare departments, state attorneys general, the Office of the Inspector General, the Office of Personnel Management, the Office for Civil Rights, the Government Accountability Office, the Federal Trade Commission, U.S. Congressional committees, the U.S. Department of Justice (DOJ), the SEC, the Internal Revenue Service, the U.S. Drug Enforcement Administration, the U.S. Department of Labor, the Federal Deposit Insurance Corporation, the Consumer Financial Protection Bureau, the Defense Contract Audit Agency, the Food and Drug Administration and other governmental authorities. Similarly, the Company’s international businesses are also subject to investigations, audits and reviews by applicable foreign governments. The Company has also been responding to subpoenas, information requests and investigations from governmental entities. The Company can provide no assurance as to the scope and outcome of these matters and no assurance as to whether its business, financial condition or results of operations will be materially adversely affected. Certain of the Company’s businesses have been reviewed or are currently under review, including for, among other matters, compliance with coding and other requirements under the Medicare risk-adjustment model. CMS has selected certain of the
Company’s local plans for risk adjustment data validation (RADV) audits to validate the coding practices of and supporting documentation maintained by health care providers and such audits may result in retrospective adjustments to payments made to the Company’s health plans.
On February 14, 2017, the DOJ announced its decision to pursue certain claims within a lawsuit initially asserted against the Company and filed under seal by a whistleblower in 2011. The whistleblower’s complaint, which was unsealed on February 15, 2017, alleges the Company made improper risk adjustment submissions and violated the False Claims Act. On February 12, 2018, the court granted in part and denied in part the Company’s motion to dismiss. In May 2018, the DOJ moved to dismiss the Company’s counterclaims, which were filed in March 2018, and moved for partial summary judgment. In March 2019, the court denied the government’s motion for partial summary judgment and dismissed the Company’s counterclaims without prejudice. The Company cannot reasonably estimate the outcome which may result from this matter given its procedural status.
v3.24.3
Dispositions and Held for Sale (Notes)
 9 Months Ended
Sep. 30, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Dispositions and Held for Sale [Text Block] Dispositions and Held for Sale
During the nine months ended September 30, 2024, the Company completed or initiated various business portfolio and asset disposition activities. The Company recorded a loss of $7.1 billion related to the sale of its Brazil operations, of which $4.1 billion related to the impact of cumulative foreign currency translation losses previously included in accumulated other comprehensive loss, and a loss of $1.2 billion related to the reclassification of the Company’s remaining South American operations as held for sale, of which $876 million related to the impact of cumulative foreign currency translation losses.
The Company also sold other businesses and assets for $1.0 billion in total consideration, with a carrying value of $241 million, and the difference reflected in the Condensed Consolidated Statement of Operations. The sales of the Company’s remaining South American assets are expected to close within a year, subject to regulatory and other customary closing conditions. Assets and liabilities held for sale have been included within prepaid and other current assets and other current liabilities on the Condensed Consolidated Balance Sheet, respectively.
The assets and liabilities of the Brazil and held for sale disposal groups as of the date of the sale and as of September 30, 2024, respectively, were as follows:
(in millions)Brazil
Disposition		Businesses
Held for Sale
Assets
Cash and cash equivalents$778 $254 
Accounts receivable and other current assets515 652 
Long-term investments788 36 
Property, equipment and capitalized software1,052 674 
Deferred tax assets1,035 — 
Goodwill and other intangible assets317 450 
Other long-term assets439 253 
Remeasurement of assets of businesses held for sale to fair value less cost to sell(1)
— (1,245)
Total assets$4,924 $1,074 
Liabilities
Medical costs payable$701 $200 
Accounts payable and other current liabilities834 395 
Other long-term liabilities136 544 
Total liabilities$1,671 $1,139 
(1)      Includes the effect of $876 million of cumulative foreign currency translation losses and $54 million of noncontrolling interests.
v3.24.3
Segment Financial Information (Notes)
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Segment Reporting Disclosure Segment Financial Information
The Company’s four reportable segments are UnitedHealthcare, Optum Health, Optum Insight and Optum Rx. For more information on the Company’s segments, see Part I, Item I, “Business” and Note 14 of Notes to the Consolidated Financial Statements included in Part II, Item 8, “Financial Statements and Supplementary Data” in the 2023 10-K.
The following tables present reportable segment financial information:
  Optum  
(in millions)UnitedHealthcareOptum HealthOptum InsightOptum RxOptum EliminationsOptumCorporate and
Eliminations		Consolidated
Three Months Ended September 30, 2024
Revenues - unaffiliated customers:
Premiums$71,624 $5,818 $— $— $— $5,818 $— $77,442 
Products— 84 41 12,506 — 12,631 — 12,631 
Services2,422 3,953 1,700 1,029 — 6,682 — 9,104 
Total revenues - unaffiliated customers
74,046 9,855 1,741 13,535 — 25,131 — 99,177 
Total revenues - affiliated customers
— 15,448 3,086 20,554 (1,130)37,958 (37,958)— 
Investment and other income
807 614 104 118 — 836 — 1,643 
Total revenues$74,853 $25,917 $4,931 $34,207 $(1,130)$63,925 $(37,958)$100,820 
Earnings from operations$4,212 $2,161 $791 $1,544 $— $4,496 $— $8,708 
Interest expense— — — — — — (1,074)(1,074)
Loss on sale of subsidiary and subsidiaries held for sale(20)— — — — — — (20)
Earnings before income taxes
$4,192 $2,161 $791 $1,544 $— $4,496 $(1,074)$7,614 
Three Months Ended September 30, 2023
Revenues - unaffiliated customers:
Premiums$66,709 $5,630 $— $— $— $5,630 $— $72,339 
Products— 61 40 10,253 — 10,354 — 10,354 
Services2,550 3,629 1,938 554 — 6,121 — 8,671 
Total revenues - unaffiliated customers
69,259 9,320 1,978 10,807 — 22,105 — 91,364 
Total revenues - affiliated customers
— 14,227 2,964 17,999 (961)34,229 (34,229)— 
Investment and other income
594 317 35 51 — 403 — 997 
Total revenues$69,853 $23,864 $4,977 $28,857 $(961)$56,737 $(34,229)$92,361 
Earnings from operations$4,592 $1,568 $1,109 $1,257 $— $3,934 $— $8,526 
Interest expense— — — — — — (834)(834)
Earnings before income taxes
$4,592 $1,568 $1,109 $1,257 $— $3,934 $(834)$7,692 
  Optum  
(in millions)UnitedHealthcareOptum HealthOptum InsightOptum RxOptum EliminationsOptumCorporate and
Eliminations		Consolidated
Nine Months Ended September 30, 2024
Revenues - unaffiliated customers:
Premiums$214,867 $17,460 $— $— $— $17,460 $— $232,327 
Products— 205 123 36,423 — 36,751 — 36,751 
Services7,339 12,006 4,807 2,590 — 19,403 — 26,742 
Total revenues - unaffiliated customers
222,206 29,671 4,930 39,013 — 73,614 — 295,820 
Total revenues - affiliated customers
— 48,641 8,887 58,208 (3,275)112,461 (112,461)— 
Investment and other income
1,870 1,386 159 236 — 1,781 — 3,651 
Total revenues$224,076 $79,698 $13,976 $97,457 $(3,275)$187,856 $(112,461)$299,471 
Earnings from operations$12,611 $5,979 $1,827 $4,097 $— $11,903 $— $24,514 
Interest expense— — — — — — (2,903)(2,903)
Loss on sale of subsidiary and subsidiaries held for sale(8,331)— — — — — — (8,331)
Earnings before income taxes
$4,280 $5,979 $1,827 $4,097 $— $11,903 $(2,903)$13,280 
Nine Months Ended September 30, 2023
Revenues - unaffiliated customers:
Premiums$201,214 $16,385 $— $— $— $16,385 $— $217,599 
Products— 156 119 30,997 — 31,272 — 31,272 
Services7,689 10,259 5,859 1,607 — 17,725 — 25,414 
Total revenues - unaffiliated customers
208,903 26,800 5,978 32,604 — 65,382 — 274,285 
Total revenues - affiliated customers
— 42,947 8,089 52,174 (2,713)100,497 (100,497)— 
Investment and other income
1,649 1,038 80 143 — 1,261 — 2,910 
Total revenues$210,552 $70,785 $14,147 $84,921 $(2,713)$167,140 $(100,497)$277,195 
Earnings from operations$13,293 $4,869 $2,984 $3,523 $— $11,376 $— $24,669 
Interest expense— — — — — — (2,416)(2,416)
Earnings before income taxes
$13,293 $4,869 $2,984 $3,523 $— $11,376 $(2,416)$22,253 
v3.24.3
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Pay vs Performance Disclosure        
Net earnings attributable to UnitedHealth Group common shareholders $ 6,055 $ 5,841 $ 8,862 $ 16,926
v3.24.3
Insider Trading Arrangements
 3 Months Ended
Sep. 30, 2024
Trading Arrangements, by Individual  
Rule 10b5-1 Arrangement Adopted false
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
v3.24.3
Basis of Presentation (Policies)
 9 Months Ended
Sep. 30, 2024
Basis of presentation [Abstract]  
Basis of Accounting, Policy [Policy Text Block] The Company has prepared the Condensed Consolidated Financial Statements according to U.S. Generally Accepted Accounting Principles (GAAP) and has included the accounts of UnitedHealth Group and its subsidiaries. The year-end condensed consolidated balance sheet was derived from audited financial statements, but does not include all disclosures required by GAAP. In accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC), the Company has omitted certain footnote disclosures that would substantially duplicate the disclosures contained in its annual audited Consolidated Financial Statements. Therefore, these Condensed Consolidated Financial Statements should be read together with the Consolidated Financial Statements and the Notes included in Part II, Item 8, “Financial Statements and Supplementary Data” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 as filed with the SEC (2023 10-K). The accompanying Condensed Consolidated Financial Statements include all normal recurring adjustments necessary to present the interim financial statements fairly.
Use of Estimates, Policy [Policy Text Block]
These Condensed Consolidated Financial Statements include certain amounts based on the Company’s best estimates and judgments. The Company’s most significant estimates relate to estimates and judgments for medical costs payable and goodwill. Certain of these estimates require the application of complex assumptions and judgments, often because they involve matters that are inherently uncertain and will likely change in subsequent periods. The impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.
Revenue [Policy Text Block] As of September 30, 2024 and December 31, 2023, accounts receivable related to products and services were $9.2 billion and $8.6 billion, respectively. As of September 30, 2024, revenue expected to be recognized in any future year related to remaining performance obligations, excluding revenue pertaining to contracts having an original expected duration of one year or less, contracts where revenue is recognized as invoiced and contracts with variable consideration related to undelivered performance obligations, was $13.0 billion, of which approximately half is expected to be recognized in the next three years.
Assets under management [Policy Text Block]
In July 2024, the Company amended and restated its Medicare Supplement Program with a membership organization (the Medicare Supplement Program). The amendments provide the Company the right to use a trade name and other intellectual property in marketing efforts for Medicare Supplement offerings. Amounts previously reported as assets under management are now included within the Company’s Condensed Consolidated Balance Sheet based upon their classification.
For periods prior to the amended and restated Medicare Supplement Program, the Company excluded the effects of certain balance sheet amounts in its Condensed Consolidated Statements of Cash Flows, while these effects are included for periods after the amendments
v3.24.3
Investments (Policies)
 9 Months Ended
Sep. 30, 2024
Investments [Abstract]  
Investment, Policy [Policy Text Block] At each reporting period, the Company evaluates available-for-sale debt securities for any credit-related impairment when the fair value of the investment is less than its amortized cost. The Company evaluated the expected cash flows, the underlying credit quality and credit ratings of the issuers, noting no significant credit deterioration since purchase. As of September 30, 2024, the Company did not have the intent to sell any of the available-for-sale debt securities in an unrealized loss position. Therefore, the Company believes these losses to be temporary.
v3.24.3
Investments (Tables)
 9 Months Ended
Sep. 30, 2024
Short-Term and Long-Term Investments [Table Text Block]
A summary of debt securities by major security type is as follows:
(in millions)Amortized
Cost		Gross
Unrealized
Gains		Gross
Unrealized
Losses		Fair
Value
September 30, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations$5,005 $5 $(182)$4,828 
State and municipal obligations7,301 23 (256)7,068 
Corporate obligations23,752 82 (781)23,053 
U.S. agency mortgage-backed securities9,209 21 (600)8,630 
Non-U.S. agency mortgage-backed securities2,832 6 (154)2,684 
Total debt securities - available-for-sale48,099 137 (1,973)46,263 
Debt securities - held-to-maturity:
U.S. government and agency obligations414 1 (2)413 
State and municipal obligations28 — (2)26 
Corporate obligations22 — — 22 
Total debt securities - held-to-maturity464 1 (4)461 
Total debt securities$48,563 $138 $(1,977)$46,724 
December 31, 2023
Debt securities - available-for-sale:
U.S. government and agency obligations$4,674 $3 $(234)$4,443 
State and municipal obligations7,636 39 (322)7,353 
Corporate obligations23,136 67 (1,186)22,017 
U.S. agency mortgage-backed securities8,982 22 (708)8,296 
Non-U.S. agency mortgage-backed securities3,023 3 (240)2,786 
Total debt securities - available-for-sale47,451 134 (2,690)44,895 
Debt securities - held-to-maturity:
U.S. government and agency obligations506 1 (6)501 
State and municipal obligations28 — (2)26 
Corporate obligations69 — — 69 
Total debt securities - held-to-maturity603 1 (8)596 
Total debt securities$48,054 $135 $(2,698)$45,491 
Investments by Contractual Maturity [Table Text Block]
The amortized cost and fair value of debt securities as of September 30, 2024, by contractual maturity, were as follows:
Available-for-SaleHeld-to-Maturity
(in millions)Amortized
Cost		Fair
Value		Amortized
Cost		Fair
Value
Due in one year or less$4,881 $4,861 $320 $319 
Due after one year through five years15,152 14,810 113 114 
Due after five years through ten years10,993 10,432 14 13 
Due after ten years5,032 4,846 17 15 
U.S. agency mortgage-backed securities9,209 8,630 — — 
Non-U.S. agency mortgage-backed securities2,832 2,684 — — 
Total debt securities$48,099 $46,263 $464 $461 
Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value
The fair value of available-for-sale debt securities with gross unrealized losses by major security type and length of time that individual securities have been in a continuous unrealized loss position were as follows:
 Less Than 12 Months12 Months or Greater Total
(in millions)Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses		Fair
Value		Gross
Unrealized
Losses
September 30, 2024
Debt securities - available-for-sale:
U.S. government and agency obligations
$894 $(7)$2,448 $(175)$3,342 $(182)
State and municipal obligations726 (6)4,278 (250)5,004 (256)
Corporate obligations3,499 (18)12,174 (763)15,673 (781)
U.S. agency mortgage-backed securities2,140 (20)5,018 (580)7,158 (600)
Non-U.S. agency mortgage-backed securities
138 (1)1,990 (153)2,128 (154)
Total debt securities - available-for-sale$7,397 $(52)$25,908 $(1,921)$33,305 $(1,973)
December 31, 2023
Debt securities - available-for-sale:
U.S. government and agency obligations
$1,270 $(7)$2,077 $(227)$3,347 $(234)
State and municipal obligations907 (7)4,063 (315)4,970 (322)
Corporate obligations1,826 (17)14,696 (1,169)16,522 (1,186)
U.S. agency mortgage-backed securities1,337 (12)5,069 (696)6,406 (708)
Non-U.S. agency mortgage-backed securities
279 (6)2,202 (234)2,481 (240)
Total debt securities - available-for-sale$5,619 $(49)$28,107 $(2,641)$33,726 $(2,690)
v3.24.3
Fair Value (Tables)
 9 Months Ended
Sep. 30, 2024
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]  
Financial Assets and Liabilities, Measured at Fair Value Recurring Basis [Table Text Block]
The following table presents a summary of fair value measurements by level and carrying values for items measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)		Total
Fair and Carrying
Value
September 30, 2024
Cash and cash equivalents$32,230$170$—$32,400
Debt securities - available-for-sale:
U.S. government and agency obligations4,682146—4,828
State and municipal obligations—7,068—7,068
Corporate obligations2722,71930723,053
U.S. agency mortgage-backed securities—8,630—8,630
Non-U.S. agency mortgage-backed securities—2,684—2,684
Total debt securities - available-for-sale4,70941,24730746,263
Equity securities1,83325651,923
Total assets at fair value$38,772$41,442$372$80,586
Percentage of total assets at fair value48 %51 %1 %100 %
December 31, 2023
Cash and cash equivalents$25,345$82$—$25,427
Debt securities - available-for-sale:
U.S. government and agency obligations4,167276—4,443
State and municipal obligations—7,353—7,353
Corporate obligations1521,80020222,017
U.S. agency mortgage-backed securities—8,296—8,296
Non-U.S. agency mortgage-backed securities—2,786—2,786
Total debt securities - available-for-sale4,18240,51120244,895
Equity securities2,46816692,553
Assets under management 1,5052,1401103,755
Total assets at fair value$33,500$42,749$381$76,630
Percentage of total assets at fair value44 %55 %1 %100 %
Fair Value Measurements, Nonrecurring [Table Text Block]
The following table presents a summary of fair value measurements by level and carrying values for certain financial instruments not measured at fair value on a recurring basis in the Condensed Consolidated Balance Sheets:
(in millions)Quoted Prices
in Active
Markets
(Level 1)		Other
Observable
Inputs
(Level 2)		Unobservable
Inputs
(Level 3)		Total
Fair
Value		Total Carrying Value
September 30, 2024
Debt securities - held-to-maturity$435 $26 $— $461 $464 
Long-term debt and other financing obligations$— $75,798 $— $75,798 $76,780 
December 31, 2023
Debt securities - held-to-maturity$524 $72 $— $596 $603 
Long-term debt and other financing obligations$— $59,851 $— $59,851 $61,449 
v3.24.3
Medical Costs Payable (Tables)
 9 Months Ended
Sep. 30, 2024
Insurance [Abstract]  
Schedule of Liability for Unpaid Claims and Claims Adjustment Expense
The following table shows the components of the change in medical costs payable for the nine months ended September 30:
(in millions)20242023
Medical costs payable, beginning of period$32,395 $29,056 
Acquisitions (dispositions), net(755)1 
Reported medical costs:
Current year197,750 180,423 
Prior years(600)(760)
Total reported medical costs197,150 179,663 
Medical payments:
Payments for current year
(165,544)(149,671)
Payments for prior years(29,095)(26,257)
Total medical payments(194,639)(175,928)
Less: medical costs payable included within businesses held for sale(200)— 
Medical costs payable, end of period$33,951 $32,792 
v3.24.3
Short-Term Borrowings and Long-Term Debt (Tables)
 9 Months Ended
Sep. 30, 2024
Debt Instrument [Line Items]  
Long-Term Debt [Table Text Block]
In March 2024, the Company issued $6.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages)Par Value
4.600% notes due April 2027
$500 
4.700% notes due April 2029
400 
4.900% notes due April 2031
1,000 
5.000% notes due April 2034
1,250 
5.375% Notes due April 2054
1,750 
5.500% Notes due April 2064
1,100 
In July 2024, the Company issued $12.0 billion of senior unsecured notes consisting of the following:
(in millions, except percentages)Par Value
Floating rate notes due July 2026
$500 
4.750% notes due July 2026
650 
4.800% notes due January 2030
1,250 
4.950% notes due January 2032
1,500 
5.150% notes due July 2034
2,000 
5.500% notes due July 2044
1,500 
5.625% notes due July 2054
2,750 
5.750% notes due July 2064
1,850 
v3.24.3
Other Intangible Assets (Tables)
 9 Months Ended
Sep. 30, 2024
Other Intangible Assets [Abstract]  
Other Intangible Assets Table Text Block
The fair values and weighted-average useful lives assigned to intangible assets as a result of transactions completed during the nine months ended September 30, 2024 consisted of the following:
(in millions, except years)Fair ValueWeighted-Average Useful Life
Customer-related$1,070 13 years
Trademarks and technology509 5 years
Other20 8 years
Total finite-lived$1,599 11 years
Total indefinite-lived - trade names, trademarks, operating licenses and certificates and other8,793 
Total intangible assets$10,392 
v3.24.3
Stockholders' Equity (Tables)
 9 Months Ended
Sep. 30, 2024
Equity [Abstract]  
Dividends Declared
The following table provides details of the Company’s dividend payments during the nine months ended September 30, 2024:
Payment DateAmount per ShareTotal Amount Paid
(in millions)
March 19$1.88 $1,729 
June 252.10 1,935 
September 242.10 1,937 
v3.24.3
Dispositions and Held for Sale (Tables)
Feb. 06, 2024
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Disposed Assets and Liabilities [Table Text Block]
The assets and liabilities of the Brazil and held for sale disposal groups as of the date of the sale and as of September 30, 2024, respectively, were as follows:
(in millions)Brazil
Disposition		Businesses
Held for Sale
Assets
Cash and cash equivalents$778 $254 
Accounts receivable and other current assets515 652 
Long-term investments788 36 
Property, equipment and capitalized software1,052 674 
Deferred tax assets1,035 — 
Goodwill and other intangible assets317 450 
Other long-term assets439 253 
Remeasurement of assets of businesses held for sale to fair value less cost to sell(1)
— (1,245)
Total assets$4,924 $1,074 
Liabilities
Medical costs payable$701 $200 
Accounts payable and other current liabilities834 395 
Other long-term liabilities136 544 
Total liabilities$1,671 $1,139 
(1)      Includes the effect of $876 million of cumulative foreign currency translation losses and $54 million of noncontrolling interests.
v3.24.3
Segment Financial Information (Tables)
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
The following tables present reportable segment financial information:
  Optum  
(in millions)UnitedHealthcareOptum HealthOptum InsightOptum RxOptum EliminationsOptumCorporate and
Eliminations		Consolidated
Three Months Ended September 30, 2024
Revenues - unaffiliated customers:
Premiums$71,624 $5,818 $— $— $— $5,818 $— $77,442 
Products— 84 41 12,506 — 12,631 — 12,631 
Services2,422 3,953 1,700 1,029 — 6,682 — 9,104 
Total revenues - unaffiliated customers
74,046 9,855 1,741 13,535 — 25,131 — 99,177 
Total revenues - affiliated customers
— 15,448 3,086 20,554 (1,130)37,958 (37,958)— 
Investment and other income
807 614 104 118 — 836 — 1,643 
Total revenues$74,853 $25,917 $4,931 $34,207 $(1,130)$63,925 $(37,958)$100,820 
Earnings from operations$4,212 $2,161 $791 $1,544 $— $4,496 $— $8,708 
Interest expense— — — — — — (1,074)(1,074)
Loss on sale of subsidiary and subsidiaries held for sale(20)— — — — — — (20)
Earnings before income taxes
$4,192 $2,161 $791 $1,544 $— $4,496 $(1,074)$7,614 
Three Months Ended September 30, 2023
Revenues - unaffiliated customers:
Premiums$66,709 $5,630 $— $— $— $5,630 $— $72,339 
Products— 61 40 10,253 — 10,354 — 10,354 
Services2,550 3,629 1,938 554 — 6,121 — 8,671 
Total revenues - unaffiliated customers
69,259 9,320 1,978 10,807 — 22,105 — 91,364 
Total revenues - affiliated customers
— 14,227 2,964 17,999 (961)34,229 (34,229)— 
Investment and other income
594 317 35 51 — 403 — 997 
Total revenues$69,853 $23,864 $4,977 $28,857 $(961)$56,737 $(34,229)$92,361 
Earnings from operations$4,592 $1,568 $1,109 $1,257 $— $3,934 $— $8,526 
Interest expense— — — — — — (834)(834)
Earnings before income taxes
$4,592 $1,568 $1,109 $1,257 $— $3,934 $(834)$7,692 
  Optum  
(in millions)UnitedHealthcareOptum HealthOptum InsightOptum RxOptum EliminationsOptumCorporate and
Eliminations		Consolidated
Nine Months Ended September 30, 2024
Revenues - unaffiliated customers:
Premiums$214,867 $17,460 $— $— $— $17,460 $— $232,327 
Products— 205 123 36,423 — 36,751 — 36,751 
Services7,339 12,006 4,807 2,590 — 19,403 — 26,742 
Total revenues - unaffiliated customers
222,206 29,671 4,930 39,013 — 73,614 — 295,820 
Total revenues - affiliated customers
— 48,641 8,887 58,208 (3,275)112,461 (112,461)— 
Investment and other income
1,870 1,386 159 236 — 1,781 — 3,651 
Total revenues$224,076 $79,698 $13,976 $97,457 $(3,275)$187,856 $(112,461)$299,471 
Earnings from operations$12,611 $5,979 $1,827 $4,097 $— $11,903 $— $24,514 
Interest expense— — — — — — (2,903)(2,903)
Loss on sale of subsidiary and subsidiaries held for sale(8,331)— — — — — — (8,331)
Earnings before income taxes
$4,280 $5,979 $1,827 $4,097 $— $11,903 $(2,903)$13,280 
Nine Months Ended September 30, 2023
Revenues - unaffiliated customers:
Premiums$201,214 $16,385 $— $— $— $16,385 $— $217,599 
Products— 156 119 30,997 — 31,272 — 31,272 
Services7,689 10,259 5,859 1,607 — 17,725 — 25,414 
Total revenues - unaffiliated customers
208,903 26,800 5,978 32,604 — 65,382 — 274,285 
Total revenues - affiliated customers
— 42,947 8,089 52,174 (2,713)100,497 (100,497)— 
Investment and other income
1,649 1,038 80 143 — 1,261 — 2,910 
Total revenues$210,552 $70,785 $14,147 $84,921 $(2,713)$167,140 $(100,497)$277,195 
Earnings from operations$13,293 $4,869 $2,984 $3,523 $— $11,376 $— $24,669 
Interest expense— — — — — — (2,416)(2,416)
Earnings before income taxes
$13,293 $4,869 $2,984 $3,523 $— $11,376 $(2,416)$22,253 
v3.24.3
Basis of Presentation (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Dec. 31, 2023
Nature of Operations
UnitedHealth Group Incorporated (individually and together with its subsidiaries, “UnitedHealth Group” and the “Company”) is a health care and well-being company with a mission to help people live healthier lives and help make the health system work better for everyone. The Company’s two distinct, yet complementary businesses — Optum and UnitedHealthcare — are working to help build a modern, high-performing health system through improved access, affordability, outcomes and experiences for the individuals and organizations the Company is privileged to serve.
  
Accounts Receivable, after Allowance for Credit Loss, Current $ 20,024 $ 21,276
Revenue, Remaining Performance Obligation, Amount $ 13,000  
Revenue, Remaining Performance Obligation, Percentage 50.00%  
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-10-01    
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period 3 years  
unh:ProductsandservicesMember    
Accounts Receivable, after Allowance for Credit Loss, Current $ 9,200 $ 8,600
v3.24.3
Investments (Narrative) (Details)
$ in Millions
Sep. 30, 2024
USD ($)
Dec. 31, 2023
USD ($)
Investments [Abstract]    
Equity Securities, FV-NI and without Readily Determinable Fair Value $ 4,900 $ 4,900
Equity Method Investments $ 1,800 $ 1,400
Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions 27,000  
Total number of security positions 41,000  
v3.24.3
Investments (Short-Term and Long-Term Investments) (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost $ 48,099 $ 47,451
Securities, Available for sale Debt Securities, Gross Unrealized Gains 137 134
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (1,973) (2,690)
Debt Securities, Available-for-sale 46,263 44,895
Held-to-maturity securities, Amortized Cost 464 603
Securities, Held to maturity, Unrecognized Holding Gain 1 1
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss (4) (8)
Debt Securities, Held-to-maturity, Fair Value 461 596
Debt Securities, Available-for-Sale and Held-to-Maturity, Fair Value 46,724 45,491
Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Loss (1,977) (2,698)
Debt Securities, Available-for-Sale and Held-to-Maturity, Cumulative Unrecognized Gain 138 135
Debt Securities, Available-for-Sale and Held-to-Maturity, Amortized Cost 48,563 48,054
Debt Securities [Member]    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale 46,263 44,895
U.S. Government and Agency Obligations [Member]    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 5,005 4,674
Securities, Available for sale Debt Securities, Gross Unrealized Gains 5 3
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (182) (234)
Debt Securities, Available-for-sale 4,828 4,443
Held-to-maturity securities, Amortized Cost 414 506
Securities, Held to maturity, Unrecognized Holding Gain 1 1
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss (2) (6)
Debt Securities, Held-to-maturity, Fair Value 413 501
State and Municipal Obligations [Member]    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 7,301 7,636
Securities, Available for sale Debt Securities, Gross Unrealized Gains 23 39
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (256) (322)
Debt Securities, Available-for-sale 7,068 7,353
Held-to-maturity securities, Amortized Cost 28 28
Securities, Held to maturity, Unrecognized Holding Gain 0 0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss (2) (2)
Debt Securities, Held-to-maturity, Fair Value 26 26
Corporate Obligations [Member]    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 23,752 23,136
Securities, Available for sale Debt Securities, Gross Unrealized Gains 82 67
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (781) (1,186)
Debt Securities, Available-for-sale 23,053 22,017
Held-to-maturity securities, Amortized Cost 22 69
Securities, Held to maturity, Unrecognized Holding Gain 0 0
Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss 0 0
Debt Securities, Held-to-maturity, Fair Value 22 69
U.S. Agency Mortgage-Backed Securities [Member]    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 9,209 8,982
Securities, Available for sale Debt Securities, Gross Unrealized Gains 21 22
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (600) (708)
Debt Securities, Available-for-sale 8,630 8,296
Non-U.S. Agency Mortgage-Backed Securities [Member]    
Schedule of Investments [Line Items]    
Debt Securities, Available-for-sale, Amortized Cost 2,832 3,023
Securities, Available for sale Debt Securities, Gross Unrealized Gains 6 3
Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax (154) (240)
Debt Securities, Available-for-sale $ 2,684 $ 2,786
v3.24.3
Investments (Amortized Cost and Fair Value of Available-for-Sale Debt Securities by Contractual Maturity) (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Schedule of Investments [Line Items]    
Due in one year or less, Amortized Cost $ 4,881  
Due after one year through five years, Amortized Cost 15,152  
Due after five years through ten years, Amortized Cost 10,993  
Due after ten years, Amortized Cost 5,032  
Total debt securities - available-for-sale, Amortized Cost 48,099 $ 47,451
Due in one year or less, Fair Value 4,861  
Due after one year through five years, Fair Value 14,810  
Due after five years through ten years, Fair Value 10,432  
Due after ten years, Fair Value 4,846  
Debt Securities, Available-for-sale 46,263 44,895
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One 320  
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five 113  
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 14  
Debt Securities, Held-to-Maturity, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10 17  
Debt Securities, Held-to-maturity 464 603
Held-to-maturity Securities, Debt Maturities, within One Year, Fair Value 319  
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five 114  
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 13  
Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10 15  
Debt Securities, Held-to-maturity, Fair Value 461 596
U.S. Agency Mortgage-Backed Securities [Member]    
Schedule of Investments [Line Items]    
Mortgage-backed securities, Amortized Cost 9,209  
Total debt securities - available-for-sale, Amortized Cost 9,209 8,982
Mortgage-backed securities, Fair Value 8,630  
Debt Securities, Available-for-sale 8,630 8,296
Non-U.S. Agency Mortgage-Backed Securities [Member]    
Schedule of Investments [Line Items]    
Mortgage-backed securities, Amortized Cost 2,832  
Total debt securities - available-for-sale, Amortized Cost 2,832 3,023
Mortgage-backed securities, Fair Value 2,684  
Debt Securities, Available-for-sale $ 2,684 $ 2,786
v3.24.3
Investments (Fair Value of Available-For-Sale Investments with Gross Unrealized Losses by Investment Type and Length of Time That Individual Securities Have Been in a Continuous Unrealized Loss Position) (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Debt Securities [Member]    
Schedule of Investments [Line Items]    
Less Than 12 Months, Fair Value $ 7,397 $ 5,619
Less Than 12 Months, Gross Unrealized Losses (52) (49)
Greater Than 12 Months, Fair Value 25,908 28,107
Greater Than 12 Months, Gross Unrealized Losses (1,921) (2,641)
Total, Fair Value 33,305 33,726
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss (1,973) (2,690)
U.S. Government and Agency Obligations [Member]    
Schedule of Investments [Line Items]    
Less Than 12 Months, Fair Value 894 1,270
Less Than 12 Months, Gross Unrealized Losses (7) (7)
Greater Than 12 Months, Fair Value 2,448 2,077
Greater Than 12 Months, Gross Unrealized Losses (175) (227)
Total, Fair Value 3,342 3,347
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss (182) (234)
State and Municipal Obligations [Member]    
Schedule of Investments [Line Items]    
Less Than 12 Months, Fair Value 726 907
Less Than 12 Months, Gross Unrealized Losses (6) (7)
Greater Than 12 Months, Fair Value 4,278 4,063
Greater Than 12 Months, Gross Unrealized Losses (250) (315)
Total, Fair Value 5,004 4,970
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss (256) (322)
Corporate Obligations [Member]    
Schedule of Investments [Line Items]    
Less Than 12 Months, Fair Value 3,499 1,826
Less Than 12 Months, Gross Unrealized Losses (18) (17)
Greater Than 12 Months, Fair Value 12,174 14,696
Greater Than 12 Months, Gross Unrealized Losses (763) (1,169)
Total, Fair Value 15,673 16,522
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss (781) (1,186)
U.S. Agency Mortgage-Backed Securities [Member]    
Schedule of Investments [Line Items]    
Less Than 12 Months, Fair Value 2,140 1,337
Less Than 12 Months, Gross Unrealized Losses (20) (12)
Greater Than 12 Months, Fair Value 5,018 5,069
Greater Than 12 Months, Gross Unrealized Losses (580) (696)
Total, Fair Value 7,158 6,406
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss (600) (708)
Non-U.S. Agency Mortgage-Backed Securities [Member]    
Schedule of Investments [Line Items]    
Less Than 12 Months, Fair Value 138 279
Less Than 12 Months, Gross Unrealized Losses (1) (6)
Greater Than 12 Months, Fair Value 1,990 2,202
Greater Than 12 Months, Gross Unrealized Losses (153) (234)
Total, Fair Value 2,128 2,481
Available-for-sale Securities, Continuous Unrealized Loss Position, Accumulated Loss $ (154) $ (240)
v3.24.3
Fair Value (Narrative) (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Fair Value [Line Items]    
Transfers Into Level 3 $ 0 $ 0
Transfers out of Level 3 0 0
Significant fair value adjustments for assets and liabilities measured on a nonrecurring basis $ 0 $ 0
v3.24.3
Fair Value (Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis) (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents $ 32,400 $ 25,427
Debt Securities, Available-for-sale 46,263 44,895
Equity Securities, FV-NI 1,923 2,553
Assets under management 0 3,755
Assets, Fair Value Disclosure 80,586 76,630
Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 46,263 44,895
U.S. Government and Agency Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 4,828 4,443
State and Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 7,068 7,353
Corporate Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 23,053 22,017
U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 8,630 8,296
Non-U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 2,684 2,786
Quoted Prices in Active Markets (Level 1) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 32,230 25,345
Equity Securities, FV-NI 1,833 2,468
Assets under management   1,505
Assets, Fair Value Disclosure 38,772 33,500
Quoted Prices in Active Markets (Level 1) [Member] | Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 4,709 4,182
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Government and Agency Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 4,682 4,167
Quoted Prices in Active Markets (Level 1) [Member] | State and Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 0 0
Quoted Prices in Active Markets (Level 1) [Member] | Corporate Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 27 15
Quoted Prices in Active Markets (Level 1) [Member] | U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 0 0
Quoted Prices in Active Markets (Level 1) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 0 0
Other Observable Inputs (Level 2) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 170 82
Equity Securities, FV-NI 25 16
Assets under management   2,140
Assets, Fair Value Disclosure 41,442 42,749
Other Observable Inputs (Level 2) [Member] | Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 41,247 40,511
Other Observable Inputs (Level 2) [Member] | U.S. Government and Agency Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 146 276
Other Observable Inputs (Level 2) [Member] | State and Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 7,068 7,353
Other Observable Inputs (Level 2) [Member] | Corporate Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 22,719 21,800
Other Observable Inputs (Level 2) [Member] | U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 8,630 8,296
Other Observable Inputs (Level 2) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 2,684 2,786
Unobservable Inputs (Level 3) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 0 0
Equity Securities, FV-NI 65 69
Assets under management   110
Assets, Fair Value Disclosure 372 381
Unobservable Inputs (Level 3) [Member] | Debt Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 307 202
Unobservable Inputs (Level 3) [Member] | U.S. Government and Agency Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 0 0
Unobservable Inputs (Level 3) [Member] | State and Municipal Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 0 0
Unobservable Inputs (Level 3) [Member] | Corporate Obligations [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 307 202
Unobservable Inputs (Level 3) [Member] | U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale 0 0
Unobservable Inputs (Level 3) [Member] | Non-U.S. Agency Mortgage-Backed Securities [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Available-for-sale $ 0 $ 0
v3.24.3
Fair Value (Financial Assets and Liabilities, Not Measured at Fair Value on a Recurring Basis) (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Dec. 31, 2023
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Held-to-maturity, Fair Value $ 461 $ 596
Debt Securities, Held-to-maturity 464 603
Fair Value, Nonrecurring [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Held-to-maturity, Fair Value 461 596
Debt and other financing obligations 75,798 59,851
Fair Value, Nonrecurring [Member] | Quoted Prices in Active Markets (Level 1) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Held-to-maturity, Fair Value 435 524
Debt and other financing obligations 0 0
Fair Value, Nonrecurring [Member] | Other Observable Inputs (Level 2) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Held-to-maturity, Fair Value 26 72
Debt and other financing obligations 75,798 59,851
Fair Value, Nonrecurring [Member] | Unobservable Inputs (Level 3) [Member]    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt Securities, Held-to-maturity, Fair Value 0 0
Debt and other financing obligations 0 0
Long-term debt and other financing obligations    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Debt and other financing obligations, carrying value $ 76,780 $ 61,449
v3.24.3
Medical Costs Payable (Narrative) (Details) - USD ($)
$ in Billions
Sep. 30, 2024
Dec. 31, 2023
Insurance [Abstract]    
Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount $ 24.1 $ 22.3
v3.24.3
Medical Costs Payable (Details) - USD ($)
$ in Millions
 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Causes of Increase (Decrease) in Liability for Unpaid Claims and Claims Adjustment Expense [Line Items]    
Medical costs payable, beginning of period $ 32,395 $ 29,056
Acquisitions (dispositions), net (755) 1
Reported medical costs:    
Current year 197,750 180,423
Prior year (600) (760)
Total reported medical costs 197,150 179,663
Medical payments:    
Payments for current year (165,544) (149,671)
Payments for prior years (29,095) (26,257)
Total medical payments (194,639) (175,928)
Less: medical costs payable included within businesses held for sale (200) 0
Medical costs payable, end of period $ 33,951 $ 32,792
v3.24.3
Short-Term Borrowings and Long-Term Debt (Details) - USD ($)
$ in Millions
Jul. 31, 2024
Mar. 31, 2024
Debt Instrument [Line Items]    
Par Value $ 12,000 $ 6,000
4.600% notes due April 2027    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage   4.60%
Par Value   $ 500
4.700% notes due April 2029    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage   4.70%
Par Value   $ 400
4.900% notes due April 2031    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage   4.90%
Par Value   $ 1,000
5.000% notes due April 2034    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage   5.00%
Par Value   $ 1,250
5.375% Notes due April 2054    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage   5.375%
Par Value   $ 1,750
5.500% Notes due April 2064    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage   5.50%
Par Value   $ 1,100
Floating rate notes due July 2026    
Debt Instrument [Line Items]    
Par Value $ 500  
4.750% notes due July 2026    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 4.75%  
Par Value $ 650  
4.800% notes due January 2030    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 4.80%  
Par Value $ 1,250  
4.950% notes due January 2032    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 4.95%  
Par Value $ 1,500  
5.150% notes due July 2034    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 5.15%  
Par Value $ 2,000  
5.500% notes due July 2044    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 5.50%  
Par Value $ 1,500  
5.625% notes due July 2054    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 5.625%  
Par Value $ 2,750  
5.750% notes due July 2064    
Debt Instrument [Line Items]    
Debt Instrument, Interest Rate, Stated Percentage 5.75%  
Par Value $ 1,850  
v3.24.3
Short-Term Borrowings and Long-Term Debt (Narrative) (Details) - USD ($)
$ in Millions
 1 Months Ended
May 31, 2024
Sep. 30, 2024
Jul. 31, 2024
Mar. 31, 2024
Debt Instrument [Line Items]        
Par Value     $ 12,000 $ 6,000
May 2024 364-day revolving bank credit facility [Member]        
Debt Instrument [Line Items]        
Line of Credit Facility, Expiration Period 364 days      
Line of Credit, Credit Facility, Maximum Borrowing Capacity $ 3,000      
May 2024 364-day delayed draw term loan        
Debt Instrument [Line Items]        
Line of Credit Facility, Expiration Period 364 days      
Line of Credit, Credit Facility, Maximum Borrowing Capacity $ 5,000      
Commercial Paper [Member]        
Debt Instrument [Line Items]        
Commercial Paper   $ 1,200    
Short-term Debt, Weighted Average Interest Rate, at Point in Time   5.40%    
v3.24.3
Other Intangible Assets (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2024
USD ($)
Other Intangible Assets Acquired [Line Items]  
Finite-lived Intangible Assets Acquired $ 1,599
Indefinite-Lived Intangible Assets Acquired 8,793
Total Acquired Intangible Assets $ 10,392
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life 11 years
Customer-Related Intangible Assets [Member]  
Other Intangible Assets Acquired [Line Items]  
Finite-lived Intangible Assets Acquired $ 1,070
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life 13 years
Trademarks And Technology Member  
Other Intangible Assets Acquired [Line Items]  
Finite-lived Intangible Assets Acquired $ 509
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life 5 years
Other Intangible Assets [Member]  
Other Intangible Assets Acquired [Line Items]  
Finite-lived Intangible Assets Acquired $ 20
Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life 8 years
v3.24.3
Shareholders' Equity (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 9 Months Ended
Sep. 24, 2024
Jun. 25, 2024
Mar. 19, 2024
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Equity [Abstract]              
Common Stock, Dividends, Per Share, Cash Paid $ 2.10 $ 2.10 $ 1.88 $ 2.10 $ 1.88 $ 6.08 $ 5.41
Payments of Ordinary Dividends, Common Stock $ 1,937 $ 1,935 $ 1,729     $ 5,601 $ 5,023
v3.24.3
Shareholders' Equity (Narrative) (Details) - shares
shares in Millions
Sep. 30, 2024
Jun. 30, 2024
Equity [Abstract]    
Share Repurchase Program, Authorized, Number of Shares   35
Share Repurchase Program, Remaining Authorized, Number of Shares 42  
v3.24.3
Commitments and Contingencies (Narrative) (Details)
$ in Billions
 9 Months Ended
Sep. 30, 2024
USD ($)
Contingencies [Line Items]  
Other Commitment $ 5
Other Commitments, Description As of September 30, 2024, the Company had entered into transaction agreements in the health care sector, subject to regulatory approval and/or other customary closing conditions. The total anticipated consideration required for these transactions, excluding the payoff of acquired indebtedness, was approximately $5 billion
v3.24.3
Dispositions and Held for Sale (Narrative) (Details)
$ in Millions
 9 Months Ended
Sep. 30, 2024
USD ($)
Brazil Disposal Group  
Disposition and Held for Sale [Line Items]  
Loss on sale of subsidiary $ (7,100)
Foreign Currency Translation Loss (4,100)
Businesses Held for Sale  
Disposition and Held for Sale [Line Items]  
Loss on sale of subsidiary (1,200)
Foreign currency translation loss (876)
Other Dispositions  
Disposition and Held for Sale [Line Items]  
Noncash or Part Noncash Divestiture, Amount of Consideration Received 1,000
Carrying Value Of Other Dispositions $ 241
v3.24.3
Dispositions and Held for Sale (Details) - USD ($)
$ in Millions
Sep. 30, 2024
Feb. 06, 2024
Brazil Disposal Group    
Disposition and Held for Sale [Line Items]    
Cash and cash equivalents   $ 778
Accounts receivable and other current assets   515
Long-term investments   788
Property, equipment and capitalized software   1,052
Deferred tax assets   1,035
Goodwill and other intangible assets   317
Other long-term assets   439
Remeasurement of assets of businesses held for sale to fair value less cost to sell   0
Total assets   4,924
Medical costs payable   701
Accounts payable and other current liabilities   834
Other long-term liabilities   136
Total liabilities   $ 1,671
Businesses Held for Sale    
Disposition and Held for Sale [Line Items]    
Cash and cash equivalents $ 254  
Accounts receivable and other current assets 652  
Long-term investments 36  
Property, equipment and capitalized software 674  
Deferred tax assets 0  
Goodwill and other intangible assets 450  
Other long-term assets 253  
Remeasurement of assets of businesses held for sale to fair value less cost to sell (1,245)  
Total assets 1,074  
Medical costs payable 200  
Accounts payable and other current liabilities 395  
Other long-term liabilities 544  
Total liabilities 1,139  
Noncontrolling interests included in determination of remeasurement losses 54  
Foreign currency translation loss $ (876)  
v3.24.3
Segment Financial Information (Narrative) (Details)
 9 Months Ended
Sep. 30, 2024
reportableSegments
Statement [Line Items]  
Number of Reportable Segments 4
v3.24.3
Segment Financial Information (Details) - USD ($)
$ in Millions
 3 Months Ended 9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Statement [Line Items]        
Premiums, revenues - unaffiliated customers $ 77,442 $ 72,339 $ 232,327 $ 217,599
Investment and other income 1,643 997 3,651 2,910
Total revenues 100,820 92,361 299,471 277,195
Earnings from operations 8,708 8,526 24,514 24,669
Interest expense (1,074) (834) (2,903) (2,416)
Loss on sale of subsidiary and subsidiaries held for sale (20) 0 (8,331) 0
Earnings before income taxes 7,614 7,692 13,280 22,253
Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 12,631 10,354 36,751 31,272
Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 9,104 8,671 26,742 25,414
Optum        
Statement [Line Items]        
Investment and other income 836 403 1,781 1,261
Total revenues 63,925 56,737 187,856 167,140
Earnings from operations 4,496 3,934 11,903 11,376
Interest expense 0 0 0 0
Loss on sale of subsidiary and subsidiaries held for sale 0   0  
Earnings before income taxes 4,496 3,934 11,903 11,376
Unaffiliated Customers        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 77,442 72,339 232,327 217,599
Total revenues 99,177 91,364 295,820 274,285
Unaffiliated Customers | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 12,631 10,354 36,751 31,272
Unaffiliated Customers | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 9,104 8,671 26,742 25,414
Unaffiliated Customers | Optum        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 5,818 5,630 17,460 16,385
Total revenues 25,131 22,105 73,614 65,382
Unaffiliated Customers | Optum | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 12,631 10,354 36,751 31,272
Unaffiliated Customers | Optum | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 6,682 6,121 19,403 17,725
Affiliated Customers        
Statement [Line Items]        
Total revenues 0 0 0 0
Affiliated Customers | Optum        
Statement [Line Items]        
Total revenues 37,958 34,229 112,461 100,497
Operating Segments | UnitedHealthcare        
Statement [Line Items]        
Investment and other income 807 594 1,870 1,649
Total revenues 74,853 69,853 224,076 210,552
Earnings from operations 4,212 4,592 12,611 13,293
Interest expense 0 0 0 0
Loss on sale of subsidiary and subsidiaries held for sale (20)   (8,331)  
Earnings before income taxes 4,192 4,592 4,280 13,293
Operating Segments | Optum Health        
Statement [Line Items]        
Investment and other income 614 317 1,386 1,038
Total revenues 25,917 23,864 79,698 70,785
Earnings from operations 2,161 1,568 5,979 4,869
Interest expense 0 0 0 0
Loss on sale of subsidiary and subsidiaries held for sale 0   0  
Earnings before income taxes 2,161 1,568 5,979 4,869
Operating Segments | Optum Insight        
Statement [Line Items]        
Investment and other income 104 35 159 80
Total revenues 4,931 4,977 13,976 14,147
Earnings from operations 791 1,109 1,827 2,984
Interest expense 0 0 0 0
Loss on sale of subsidiary and subsidiaries held for sale 0   0  
Earnings before income taxes 791 1,109 1,827 2,984
Operating Segments | Optum Rx        
Statement [Line Items]        
Investment and other income 118 51 236 143
Total revenues 34,207 28,857 97,457 84,921
Earnings from operations 1,544 1,257 4,097 3,523
Interest expense 0 0 0 0
Loss on sale of subsidiary and subsidiaries held for sale 0   0  
Earnings before income taxes 1,544 1,257 4,097 3,523
Operating Segments | Unaffiliated Customers | UnitedHealthcare        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 71,624 66,709 214,867 201,214
Total revenues 74,046 69,259 222,206 208,903
Operating Segments | Unaffiliated Customers | UnitedHealthcare | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 0 0 0 0
Operating Segments | Unaffiliated Customers | UnitedHealthcare | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 2,422 2,550 7,339 7,689
Operating Segments | Unaffiliated Customers | Optum Health        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 5,818 5,630 17,460 16,385
Total revenues 9,855 9,320 29,671 26,800
Operating Segments | Unaffiliated Customers | Optum Health | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 84 61 205 156
Operating Segments | Unaffiliated Customers | Optum Health | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 3,953 3,629 12,006 10,259
Operating Segments | Unaffiliated Customers | Optum Insight        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 0 0 0 0
Total revenues 1,741 1,978 4,930 5,978
Operating Segments | Unaffiliated Customers | Optum Insight | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 41 40 123 119
Operating Segments | Unaffiliated Customers | Optum Insight | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 1,700 1,938 4,807 5,859
Operating Segments | Unaffiliated Customers | Optum Rx        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 0 0 0 0
Total revenues 13,535 10,807 39,013 32,604
Operating Segments | Unaffiliated Customers | Optum Rx | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 12,506 10,253 36,423 30,997
Operating Segments | Unaffiliated Customers | Optum Rx | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 1,029 554 2,590 1,607
Operating Segments | Affiliated Customers | UnitedHealthcare        
Statement [Line Items]        
Total revenues 0 0 0 0
Operating Segments | Affiliated Customers | Optum Health        
Statement [Line Items]        
Total revenues 15,448 14,227 48,641 42,947
Operating Segments | Affiliated Customers | Optum Insight        
Statement [Line Items]        
Total revenues 3,086 2,964 8,887 8,089
Operating Segments | Affiliated Customers | Optum Rx        
Statement [Line Items]        
Total revenues 20,554 17,999 58,208 52,174
Optum Eliminations        
Statement [Line Items]        
Investment and other income 0 0 0 0
Total revenues (1,130) (961) (3,275) (2,713)
Earnings from operations 0 0 0 0
Interest expense 0 0 0 0
Loss on sale of subsidiary and subsidiaries held for sale 0   0  
Earnings before income taxes 0 0 0 0
Optum Eliminations | Unaffiliated Customers        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 0 0 0 0
Total revenues 0 0 0 0
Optum Eliminations | Unaffiliated Customers | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 0 0 0 0
Optum Eliminations | Unaffiliated Customers | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 0 0 0 0
Optum Eliminations | Affiliated Customers        
Statement [Line Items]        
Total revenues (1,130) (961) (3,275) (2,713)
Corporate and Eliminations        
Statement [Line Items]        
Investment and other income 0 0 0 0
Total revenues (37,958) (34,229) (112,461) (100,497)
Earnings from operations 0 0 0 0
Interest expense (1,074) (834) (2,903) (2,416)
Loss on sale of subsidiary and subsidiaries held for sale 0   0  
Earnings before income taxes (1,074) (834) (2,903) (2,416)
Corporate and Eliminations | Unaffiliated Customers        
Statement [Line Items]        
Premiums, revenues - unaffiliated customers 0 0 0 0
Total revenues 0 0 0 0
Corporate and Eliminations | Unaffiliated Customers | Products        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 0 0 0 0
Corporate and Eliminations | Unaffiliated Customers | Services        
Statement [Line Items]        
Revenue from Products and Services - unaffiliated customers 0 0 0 0
Corporate and Eliminations | Affiliated Customers        
Statement [Line Items]        
Total revenues $ (37,958) $ (34,229) $ (112,461) $ (100,497)
UnitedHealth (NYSE:UNH)
Historical Stock Chart
From Oct 2024 to Nov 2024 Click Here for more UnitedHealth Charts.
UnitedHealth (NYSE:UNH)
Historical Stock Chart
From Nov 2023 to Nov 2024 Click Here for more UnitedHealth Charts.